

2024 International Congress Abstracts: Full Presentation Schedule

All accepted abstracts will be published in an e-supplement to the *Movement Disorders* journal online edition.

All submitted abstracts become the property of MDS.

#:	Abstract Title	Presentation Date:	Time:	Category:
1	Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
2	Plasma MicroRNA Expression Profiling in patients with Multiple System Atrophy and Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
3	Altered activity of lysosomal hydrolases in monocyte-derived macrophages as potential biomarker for differential diagnosis of multiple system atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
4	A Phase 2 Study of ATH434 a Novel Inhibitor of α -Synuclein Aggregation for the Treatment of Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
5	Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
6	Serotonin Transporter Dynamics in Multiple System Atrophy: Insights from 123I-FP-CIT SPECT Imaging	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
7	Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
8	Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
9	Syllable-based speech characteristics as potential biomarker for differential diagnosis of Parkinson's disease, multiple system atrophy, and cerebellar ataxia	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
10	Clinical and neuroimaging factors associated with survival in Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
12	Prospective Study of Gait and Multimodal MRI Biomarkers for Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
13	Intraepidermal Nerve Fiber Density at Baseline Associates with One-year Clinical Disease Progression in Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA

14	Role of the Alpha-synuclein Seed Amplification Assay in Parkinson's Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
15	Catalan MSA Registry (CMSAR): Applying new Clinical Criteria and Biomarkers for Increasing Diagnostic Accuracy, is New Better?	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
16	TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein - A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
17	A 3D CNN Approach for the Classification of Multiple System Atrophy using Multimodal Multicentric MRI	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
18	Unsupervised Learning Approach for Pathology-Based Subtyping and Staging Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
19	Pain types in multiple system atrophy: results from a community-based survey	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
20	Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
21	Seed Amplification Assay for the differentiation of α Syn seed subtypes	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
22	Multiple System Atrophy in a Patient with Normal Pressure Hydrocephalus	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
23	Explore cellular heterogeneities of orbitofrontal cortex in multiple system atrophy using spatial transcriptomics	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
24	Combining alpha-synuclein PET and seeded amplification assays to improve the diagnostic accuracy of Multiple System Atrophy of the Parkinsonian subtype (MSA-P)	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
25	The Clinical Implication of Dysphagia in Patients with Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
26	Correlation of Imaging Markers with Clinical Features in Multiple System Atrophy Patients	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
27	Optical Coherence Tomography Findings in Multiple System Atrophy: Insights into Disease Subtypes, Clinical Correlations, and Dopaminergic Degeneration	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
28	Characteristics of Language Abnormalities in Multiple System Atrophy and Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA

29	Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
30	Lyme disease presenting as a rapidly progressive MSA-C look alike	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
31	Prognostic role of postganglionic cardiovascular dysfunction in Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
32	Prevalence of autonomic symptoms in Multiple System Atrophy on the background of probable RBD	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
35	Treatment Patterns and Comorbidities Associated with Multiple System Atrophy: A Comparative Study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
36	Familial Multiple System Atrophy-Mimics: Importance of Comprehensive Evaluation	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
37	Heterogeneity of multiple system atrophy with an analysis of the clinical case	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
38	Posterior Fossa Arachnoid Cysts In Two Patients With Suspected Multiple System Atrophy – Cerebellar Type	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
39	Increasing diagnostic accuracy of Multiple System Atrophy – A Videolibrary on clinical and imaging features	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: MSA
41	Dermal 4R-Tau seeding as a novel biomarker for Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
42	Legmain/Asparaginyl endopeptidase-resistant tau fibril fold produces corticobasal degeneration-specific C-terminal tau fragment	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
43	Is cathepsin D a good target for therapy in Tau-related conditions?	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
44	Inclusion of PSP-Parkinsonism (PSP-P) phenotype in clinical trials - power calculation	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
45	Tau Deposition in Locus Coeruleus is Associated with Rapid Eye Movement Sleep Behavior Disorder in Progressive Supranuclear Palsy.	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
46	Rapid Cognitive Deterioration and Related Factors in Progressive Supranuclear Palsy: a One-Year Follow-up Study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
47	Longitudinal progress and clinical relevance of 18F-Florzolotau PET in patients with PSP: a one-year follow-up study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD

48	Nigral Neuroinflammation and Dopaminergic Neurons in PD, MSA and PSP: A Comparative Clinicopathological Study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
49	Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
50	Paraneoplastic neurological syndrome mimicking a progressive supranuclear palsy: a case series	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
51	Clinical characteristics and Brain atrophy pattern in the prospective multicenter cohort of Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
52	Development and Validation of a Clinical Scale for Distinguishing Multiple System Atrophy from 4-Repeat Tauopathies	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
53	Environmental risk factors and demographic of patients with Progressive Supranuclear Palsy from Argentina	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
54	The Landscape of Interdisciplinary Care for Atypical Parkinsonism: A Qualitative Study from the CurePSP Centers of Care	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
55	¹⁸ F-Florzolotau Positron Emission Tomography Imaging Correlates with Regional Brain Atrophy and Plasma Biomarkers in Tauopathy Parkinsonism Syndrome	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
56	Peripheral immune profile and neutrophil-to-lymphocyte ratio in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
57	Video-oculography for enhancing the diagnostic accuracy of early oculomotor dysfunction in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
59	Combined application of alpha-synuclein and 4-repeat tau seed amplification assays for the differential diagnosis of parkinsonian disorders	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
60	Identification of underlying Lewy body pathology in primary tauopathies by α -synuclein seed amplification assay	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
61	The links between frontal deficits and levels of inflammatory parameters in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
62	Peripheral inflammation severity in differential diagnosis of progressive supranuclear palsy and multiple system atrophy – usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and neutrophil-to-high-density lipoprotein-cholesterol ratio	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
63	Cholinergic denervation is more severe in patients with Parkinson disease compared to Progressive Supranuclear Palsy-Parkinsonism subtype: A [¹⁸ F]-FEOBV PET study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD

64	Spectrum of Sleep abnormalities in Patients with Progressive supranuclear palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
65	Regional tau burden patterns and their associations with clinical severity in progressive supranuclear palsy (PSP)-Richardson's syndrome and PSP- predominant parkinsonism: a prospective cohort study	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
66	Metabolic Progressive Subtypes in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
67	Decoding non-IPD Parkinsonism - A Comparative Analysis of Atypical and Secondary Parkinsonism	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
68	Metabolic Covariance Networks in Progressive Supranuclear Palsy Revealed by Spatial independent component analysis	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
69	Frequency of Falls as a Presenting Symptom and Its Effect in Prognosis in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
70	Neuropsychiatric symptoms in patients with probable Progressive supranuclear palsy in reference centers of Valle del Cauca- Colombia	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
71	Cytokine Profiles as Biomarkers for Neurodegenerative Diseases: An inflammatory study on Parkinson's Disease and Tauopathies	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
72	Diagnostic Spectrum in a Cohort of Atypical Atypical Parkinsonism	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
73	The Clinical Landscape of Progressive Supranuclear Palsy in an Underserved Community from Southwestern Colombia	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
74	Remote Digital Longitudinal Assessment of Speech, Fluency and Cognitive Function in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
75	Hydrocephalic Progressive Supranuclear Palsy: An Underrecognized Entity	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
76	Early Syndromes and Clinicopathologic Progression in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
77	Progressive freezing of gait in atypical parkinsonism. A Possible Progressive Supranuclear Palsy phenotype.	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
78	PSP: a Clinical Case	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
79	Validation of Inertial Monitoring Units for Gait Assessment in Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD

80	Pisa Syndrome as an early presenting feature of Corticobasal Ganglionic degeneration [CBGD]	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
81	Ethnic Diversity and Symptomatology in Parkinson's Disease with a Focus on Falls and Vertical Gaze Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
82	Stiff Person Syndrome developing into Corticobasal Syndrome: a case report.	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
83	Bedside Assessment of Downgaze Palsy by Amplitude in Patients with Progressive Supranuclear Palsy	Saturday, September 28	13:00-15:00	Parkinsonism, Atypical: PSP, CBD
85	Study of the functional role of circulating extracellular vesicles as mediators of inflammation in cellular models of Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
86	Unveiling the Link: Insulin's Novel Role in Modulating α -Synuclein Accumulation in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
87	Association between use of Furosemide and Risk of Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
88	Plasma Biomarkers of Alzheimer's Pathology Identify Prodromal Dementia with Lewy bodies	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
89	Sex Differences for Regional Lewy Body Pathology in Pathologically-Defined Lewy Body Dementia	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
90	Impact of Prior Head Trauma on Parkinson's Disease Experience	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
91	Prediction of amyloid positivity in Dementia with Lewy bodies using the early-phase 18F-FP-CIT PET images	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
92	Path To Prevention (P2P) Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study Update	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
93	18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
94	Mild Behavioral Impairment in Lewy body disease: a potential marker of phenoconversion and disease severity	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
95	α -Synuclein Seed Amplification Assay Amplification Parameters and Progression in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
96	Salivary and Plasma Heme Oxygenase-1 Concentration as a New Potential Biomarker in Parkinson Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia

97	Free-water MRI Correlates of Pareidolia in Dementia with Lewy Bodies	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
98	Plasma pTau181 and pTau217 Detect Amyloid Co-pathology and Have Specific Cut-offs in Lewy Body Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
99	AI for Personalized Medication Management in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
100	String Vessel Formation Regionally Increases in Long Duration Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
101	Progression of motor asymmetry in the MDS-UPDRS III in Parkinson's Disease with and without REM Sleep Behavior Disorder over five years	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
102	Utilization of Skin Punch Biopsy for the Diagnosis of Alpha-synucleinopathy in Clinical Practice	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
103	Cardiovascular Associations of Cortical Lewy Bodies in the Oldest Old: The 90+ study	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
104	Assessing the Accuracy of Clinical Diagnostic Criteria of Lewy Body Dementia for Detection of Lewy Body Disease in the Oldest-Old: The 90+ Study	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
105	Accuracy of Clinical features for Substantia Nigra Hypopigmentation and Cortical Lewy Body Presence in the Oldest-Old: The 90+ Study	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
106	Preventing Treatment Disruptions: The Crucial Role of Outpatient Nurses and Multidisciplinary Collaboration in Managing Skin Complications during Foslevodopa/Foscarbidopa Therapy	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
107	Identification of Novel Blood Biomarkers among Data-Driven Parkinson's Disease Clusters in Asian Populations	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
108	New α -Synuclein Strain Biomarker in Parkinson's Disease and Related Dementia	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
109	Passive smartphone speech monitoring in isolated rapid eye movement sleep behaviour disorder	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
110	Impact of Temperature Variation on Emergency Department Visits for Parkinson's Disease Patients Amongst Two Sites	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
111	Association between environmental phthalates exposure and gut microbiota and metabolome in dementia with Lewy bodies	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
112	Visual Hallucinations and α -Synuclein Oligomers in Dementia with Lewy Bodies (DLB)	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia

113	CSF Neurogranin Levels Are Decreased in Parkinson Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
114	MDS Clinical Supportive Criteria for Parkinson's Disease are Associated with α -Synuclein Seed Amplification Assay Status	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
115	Exploring Vestibulopathy in PD: Distinguishing PD from Age-related Presbyvestibulopathy via Dynamic Gait and Balance Assessment	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
116	Establishing α -Synuclein Seeding Activity in Saliva as a Noninvasive Diagnostic Biomarker for Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
117	Concordance of Neuropathologic Diagnosis of Lewy Body Disease with Baseline Alpha-Synuclein Seed Amplification Assay in PPMI	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
118	Increased cholinergic activity in specific brain regions associated with the presence of dyskinesias in Parkinson's disease: A [18F]-FEOBV PET study	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
119	Cholinergic Brain Signature of Presbyvestibulopathy in Parkinson's Disease: Exploring Central Nervous System Vestibular Mechanisms	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
120	Age-associated presbyvestibulopathy is more severely abnormal in PD compared to the older controls	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
121	Understanding Sleep-wake Disturbances in Dementia with Lewy Bodies Using Parametric and Non-parametric Measures in Wrist Actigraphy	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
122	EEG dominant frequency as a potential biomarker of cognition in Lewy body diseases.	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
123	α -Synuclein Pathology Across Movement Disorders and Neurodegenerative Diseases by Seed Amplification Assay	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
124	Association of β -Amyloid Load on PET with Cognitive Profiles Across the Lewy Body Diseases Continuum	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
125	Beyond Clinical Presentation: Incorporating Neuroimaging and Biofluid Markers to Predict Progression of Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
126	Early Dementia with Lewy Bodies and Parkinson's Disease with RBD: two faces of the same coin?	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
127	Oral health in Parkinson's disease patients from countries with different economies: preliminary results of the OralPark study.	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
128	Association between Kinetic Parameters of Alpha-synuclein Seed Amplification Assay in CSF and Parkinson's Disease Subtypes.	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia

129	Prediction of Time-to-Phenoconversion to Parkinsonism in Idiopathic REM Sleep Behavior Disorder (iRBD)	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
130	Association Between DPP-4 Inhibitors Use and Risk of Dementia: A Meta-analysis Using Real-world Data	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
131	Baseline and Longitudinal NSD-ISS Staging of the PPMI Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
132	Parkinson's disease in a Special Population -Diagnosis and treatment of Parkinson's disease in cases of psychiatric disorders treated with dopamine receptors antagonists-	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
133	A case of progressive supranuclear palsy followed by dementia with Lewy bodies	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
134	Clinical Profile of Motor Complications in Parkinson's Disease Patients at A National Tertiary Hospital In Indonesia	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
135	A Case of Concurrent Wilson Disease and Parkinson Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
136	Focused Ultrasound Therapy Treatment for Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease and Lewy Body Dementia
137	Manganese-induced Parkinsonism Vs Rotenone-induced Parkinsonism: Animal Life Matters!	Saturday, September 28	13:00-15:00	Parkinsonism, Others
138	SARS-CoV-2 induced neurodegeneration in oxidative stress and genetic models of Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinsonism, Others
139	Assessing Feasibility of Using Phone Video Data in Diagnosing Parkinsonism	Saturday, September 28	13:00-15:00	Parkinsonism, Others
140	Trihexyphenidyl Use in a Parkinsonian Phenotype of Gerstman-Sträussler-Scheinker Syndrome	Saturday, September 28	13:00-15:00	Parkinsonism, Others
141	Vestibular impairment, turning direction and turn progression in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinsonism, Others
142	Clinical Utility of Synuclein Skin Biopsy in the Initial Diagnosis and Evaluation of Parkinsonian Disorders	Saturday, September 28	13:00-15:00	Parkinsonism, Others
143	Early-onset Parkinsonism as Presenting Manifestation of CADASIL in a Mexican Woman with NOTCH3 c.1732C>T Pathogenic Variant	Saturday, September 28	13:00-15:00	Parkinsonism, Others
144	A Cross-Sectional Study of Sleep Disturbances in Parkinson's Disease Patients at a Tertiary Neurological Center in Nepal	Saturday, September 28	13:00-15:00	Parkinsonism, Others

145	Perry Syndrome due to a DCTN1 novel variant	Saturday, September 28	13:00-15:00	Parkinsonism, Others
146	Quantitative Assessment of X-linked Dystonia-Parkinsonism Using Wearable Sensing Technology	Saturday, September 28	13:00-15:00	Parkinsonism, Others
147	Changes in Postural Control of Patients with Normal Pressure Hydrocephalus After Lumbar Puncture	Saturday, September 28	13:00-15:00	Parkinsonism, Others
148	Impact of Striatal Degeneration on Patient Reported Symptoms in Idiopathic Normal Pressure Hydrocephalus	Saturday, September 28	13:00-15:00	Parkinsonism, Others
149	Pallidotomy as a Therapeutic Option for Patients with Advanced Parkinson's Disease: Case Study	Saturday, September 28	13:00-15:00	Parkinsonism, Others
150	Real-world use of biomarkers for Parkinsonism: Should I do this (pSyn) or DaT?	Saturday, September 28	13:00-15:00	Parkinsonism, Others
151	New onset movement disorders following COVID-19 infection	Saturday, September 28	13:00-15:00	Parkinsonism, Others
153	Influence of immigration on Parkinson's disease: analysis of clinical presentation.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
154	Peripheral immunity and clinical phenotypes in patients with ventriculomegaly	Saturday, September 28	13:00-15:00	Parkinsonism, Others
155	Parkinson Disease. An innovative Approach	Saturday, September 28	13:00-15:00	Parkinsonism, Others
156	Mixed Brain Pathology in Neurodegenerative Parkinsonism and Dementia	Saturday, September 28	13:00-15:00	Parkinsonism, Others
157	Behind the wheel with Parkinson's-Older patients' review	Saturday, September 28	13:00-15:00	Parkinsonism, Others
158	Risk Factors Of Parkinson's Disease A Case-Control Study In Tunisian Patients	Saturday, September 28	13:00-15:00	Parkinsonism, Others
159	Identifying key symptoms associated to parkinsonism other than Parkinson's Disease: a case series	Saturday, September 28	13:00-15:00	Parkinsonism, Others
160	Association between Antiepileptic Drugs and Parkinson's Disease: A Strong or Weak Link?	Saturday, September 28	13:00-15:00	Parkinsonism, Others
161	Integrating Parkinson's Plus Cohorts into the Global Parkinson's Genetics Program	Saturday, September 28	13:00-15:00	Parkinsonism, Others

162	Non motor symptoms assessment in Primary Familial Brain Calcification, survey on a cohort	Saturday, September 28	13:00-15:00	Parkinsonism, Others
163	The Impact of Camp Lejeune Toxins on the Development of Parkinsonisms and Movement Disorders	Saturday, September 28	13:00-15:00	Parkinsonism, Others
164	Driving assessment in older patients with Parkinson's in United Kingdom.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
165	24-Hour Ambulatory Blood Pressure Monitoring and Dipping Patterns in Parkinson's Disease and Multiple System Atrophy	Saturday, September 28	13:00-15:00	Parkinsonism, Others
166	Case Report: An Unusual Case of Corticobasal Syndrome	Saturday, September 28	13:00-15:00	Parkinsonism, Others
167	The Challenges of Very Late-Onset Parkinson's Disease: Perspectives from Patients, Primary Caregivers and Attending Physicians.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
168	The impact of stimulation setting on Battery Longevity in Deep Brain Stimulation	Saturday, September 28	13:00-15:00	Parkinsonism, Others
169	Immune cell traits and Parkinson's disease: A Mendelian randomization study	Saturday, September 28	13:00-15:00	Parkinsonism, Others
170	Post-stroke Movement Disorders: A Systematic Review of the Clinical Spectrum, Neuroanatomy, and Demographic Characteristics of 577 Published cases	Saturday, September 28	13:00-15:00	Parkinsonism, Others
171	Immunomodulatory Effects Of Covid-19 Vaccination On Inflammatory And Neurotrophic Factors In Parkinson's Disease: Insights From Clinical Subtypes	Saturday, September 28	13:00-15:00	Parkinsonism, Others
172	Impact of Striatal Degeneration on Clinical Phenotype in Idiopathic Normal Pressure Hydrocephalus: A Comparative Analysis	Saturday, September 28	13:00-15:00	Parkinsonism, Others
173	Body Mass Index as a Possible Poor Prognostic Factor in Motor and Postural Condition Through the Evaluation of MDS-UPDRS 3.3 - 3.18 in Patients with Parkinson's.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
174	Exploring Retrospectively the Predisposing Factors of Sleep Disorders in Parkinson's Disease.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
175	Initial Results After Launch of Best Practice Advisory for Contraindicated Agents in Parkinson's Disease and Related disorders	Saturday, September 28	13:00-15:00	Parkinsonism, Others
176	Parkinsonism in setting of hypoparathyroidism	Saturday, September 28	13:00-15:00	Parkinsonism, Others
177	Characterization of Autoimmune Parkinsonism. A case series	Saturday, September 28	13:00-15:00	Parkinsonism, Others

178	Mitigating The Impact Of Covid-19 On Parkinson's Disease: Insights From Vaccination Strategies	Saturday, September 28	13:00-15:00	Parkinsonism, Others
179	Comparison of Composite Method Calculations for Monitoring Disease Progression in Early Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinsonism, Others
180	Delayed Parkinsonism as a Delayed Neurological Sequele in Carbon Monoxide Intoxication: A Rare Case Report	Saturday, September 28	13:00-15:00	Parkinsonism, Others
181	Cognitive Side Effects to Initial Levodopa Exposure as a "Red Flag": A Retrospective Study	Saturday, September 28	13:00-15:00	Parkinsonism, Others
182	PSP-Like Syndrome Associated with Dysautonomic Findings as a Presentation of an Anti-Igln5 Antibody-Related Encephalopathy	Saturday, September 28	13:00-15:00	Parkinsonism, Others
183	Giant Aneurysm Causing Parkinsonism and REM Sleep Disorder	Saturday, September 28	13:00-15:00	Parkinsonism, Others
184	Hospital Care Learning Collaborative: Sharing strategies to address the Parkinson's Foundation Inpatient Clinical Care Standards	Saturday, September 28	13:00-15:00	Parkinsonism, Others
185	PKG-Ethnicity project: An initial analysis of ethnical differences in Parkinson's KinetoGraph (PKG) results between white and non-white ethnic groups	Saturday, September 28	13:00-15:00	Parkinsonism, Others
186	Broadening the Spectrum of Movement Disorders in Steroid-responsive Encephalopathy associated with Autoimmune Thyroiditis	Saturday, September 28	13:00-15:00	Parkinsonism, Others
187	Coat test: a bedside timed test for quantifying motor function in Parkinson's disease patients.	Saturday, September 28	13:00-15:00	Parkinsonism, Others
188	The Differences in the Perception of Parkinson's Disease-related Motor Complications between Patients and Physicians	Saturday, September 28	13:00-15:00	Parkinsonism, Others
189	Disease-related comprehensive motor pattern derived from 2D single RGB video as a biomarker for early and prodromal Parkinson disease	Saturday, September 28	13:00-15:00	Parkinsonism, Others
190	Atypical Parkinsonism Secondary to Recurrent Deep Vein Thrombosis with Associated Intracranial Dural Fistula	Saturday, September 28	13:00-15:00	Parkinsonism, Others
191	Normal pressure hydrocephalus in two Parkinson's disease patients with deep brain stimulation – co-occurrence or complication	Saturday, September 28	13:00-15:00	Parkinsonism, Others
192	Subdural Hematoma Leading to Subacute Secondary Parkinsonism	Saturday, September 28	13:00-15:00	Parkinsonism, Others
193	Parkinsonism Associated with Twinkle Gene Mutation	Saturday, September 28	13:00-15:00	Parkinsonism, Others

194	Unique Presentation of SPG 15 as Juvenile Levodopa Responsive Parkinsonism: A Case Report	Saturday, September 28	13:00-15:00	Parkinsonism, Others
195	Parkinsonism due to Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Responsive to Carbidopa/Levodopa	Saturday, September 28	13:00-15:00	Parkinsonism, Others
200	Assessment Of The Effect Of Sleep Deprivation And Essential Amino Acid Deficient Diet (Tryptophan) On Growth And Cognition In Wistar Rats	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
201	Dual-Task Cost of Walking While Using a Smartphone: A Comparison Study of Older Adults with and Without Cognitive Decline	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
202	CANVAS: think to assess cognition!	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
203	Eye movements and cognitive function	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
204	The course of cognitive impairment in Parkinson's disease patients with Covid-19	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
205	Exploring the Prevalence of Subjective Cognitive Decline and Mild Cognitive Impairment in Participants of the Luxembourg Healthy Ageing Study	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
207	Blood-brain Barrier Breakdown in Dementia with Lewy Bodies	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
208	Managing Cognitive Decline in Vascular Dementia with Associated Parkinsonism	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
209	Subjective Cognitive Decline in a National Population-based probable RBD Survey	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
210	Dopaminergic alterations in patients with Alzheimer's disease	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
211	Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
212	Wilson Disease Presenting as Rapidly Progressive Dementia	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
213	Genetic Architecture Of Movement Disorder And Its Association With Consanguinity In Pashtoon Population	Saturday, September 28	13:00-15:00	Cognitive Disorders (non-PD)
216	Cognitive status in patients with akinetic-rigid and tremor-dominant forms of Parkinson's disease in Tajikistan.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions

217	A Systematic Review of Transcranial Magnetic Stimulation Clinical Trials in Parkinson's Disease Patients with Mild Cognitive Impairment	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
218	The impact of cognitive impairment and Alzheimer's disease neuropathological changes on gait and falls in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
219	Association between Parkinsonism, Parkinson's Disease and Cognitive Impairment and Incidence of Dementia in People with Parkinsonism and Parkinson's Disease in Latin America: A 10/66 Dementia Research Group Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
220	Cognitive function of patients with Parkinson's Disease after Deep Brain Stimulation: a gene- and variant-based approach	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
221	Spatial Memory and Processing Speed as Cornerstones in Predicting Falls in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
222	Influence of the Level of Education on the Change in Cognitive Function in Parkinson's Disease. A 5-year Follow-up Study.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
223	Walking reduced the risk of Parkinson's disease dementia: a retrospective longitudinal follow-up study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
224	Predicting cognitive phenotypes in de novo Parkinson's disease: an fMRI data-driven approach.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
225	Assessment of cognitive impairment in Parkinson's disease in under-represented ethnic groups-The London-Dhaka Parkinson's Cognitive Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
226	Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
227	The Cats-and-Dogs Test Predicts Cognitive Impairment in Parkinson's Disease in a Diverse Population	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
228	SelfCog®: A 15-min Digitized Cognitive Battery To Measure Cognitive Deficit In Parkinson Disease (PD) Patients	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
229	Cognitive Performance in Early Neuronal alpha-Synuclein Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
230	Evaluating Cognitive Status in Parkinson's Disease Using a Software-based Eye-Tracking Platform: Preliminary Results of the PALOMA Clinical Trial	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
231	The East London Parkinson Disease Project: updated results from engaging a diverse population in research	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions

232	The Impact of Parkinson's Disease on Causal Perception	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
233	Attention/Working memory and Executive Tests in Parkinson's disease: Review, Critique and Recommendations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
234	Creation and Performance of a Cognitive Summary Score in de novo Parkinson's Disease: Results from the PPMI Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
235	Impact of Cognitive Impairment on Mobility and Linguistic Metrics During a Dual-task in PD	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
236	Detecting Mild Cognitive Impairment in Parkinson's Disease using Speech Markers	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
238	Incident & Prevalent Dementia in Individuals with Parkinson's Disease in the Framingham Heart Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
239	Periodic and Aperiodic EEG Correlates of Cognition in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
240	Clinical and Neuroimaging Biomarker Predictors of Cognitive Dysfunction In Parkinson's Disease: A Study Using PPMI Data	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
241	Orthostatic Hypotension is Associated with Worse Verbal Letter Fluency and Lower Neural Efficiency While Upright in Parkinson's Disease: A Pilot Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
242	Cognitive Impairment in a Cohort of Patients with DBS for parkinson's disease treatment from a multicentric Cohort in Colombia	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
243	Frontal dysfunction as a cognitive biomarker in prodromal Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
244	Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Activities of Daily Living, Behavioural and Cognitive ability (A-B-C) of PD Patients: A Randomized Controlled Trial	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
245	To develop and study the efficacy of Telephonic Psychotherapy on the Global Neuropsychological functioning of PD Patients: An RCT	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
246	Misdiagnosis of Cognitive Impairment in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
247	How Does Mild Cognitive Impairment in Parkinson's Disease Affect Communication Abilities?	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
248	Clinical and neurological features of the course of Parkinsonism disease in patients with CKD with cystatin C disorder	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions

249	Cleaved plasma kininogen is associated with unfavorable cognitive outcome in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
250	Cognitive, Non-Motor, and Quality of Life Outcomes After STN or GPi DBS for Parkinson's Disease: An Interim Report from the ADROIT NAPA Sub-Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
252	Characterisation and longitudinal significance of subjective cognitive decline in GBA and LRRK2 Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
253	The Prevalence of Parkinson's Disease with Dementia in a door to door survey done in a rural district in Hai, Kilimanjaro.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
254	Cognitive profile of Parkinson's disease (PD) in the Framingham Heart Study (FHS)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
256	Critically Evaluating Best Practice Guidelines for Cognitive Impairment in Parkinson's Disease: A Systematic Review (PDCogniCare)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
257	Neuropsychological Tests of Language, Memory, and Visuospatial Function in Parkinson's Disease: Review, Critique and Recommendations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
258	"This Abstract Presents the Most Important Scientific ____." A New Sentence Completion Test for Parkinson's Disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
259	Assessing the Impact of Deep Brain Stimulation on Cognitive Impairment in Parkinson's Disease: a longitudinal study.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
260	Investigating Cognitive Impairments in early Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
261	Neuropsychological Predictors of Cognitive Decline in Parkinson's Disease: A Systematic Review (PDCogniCare)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
262	Apathy produces selective deficits in cognitive function when controlling for depression in patients with Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
263	Correlation Between Mild Cognitive Impairment and Levodopa Induced Dyskinesia in Parkinson's Disease Patients	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
264	Cognitive Reserve and Motor Subtypes of Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
266	Subtyping Parkinson's Disease Mild Cognitive Impairment (PD-MCI) by Cholinergic Degeneration	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
267	Cognitive Reserve may influence Executive Function in Parkinson's Disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions

268	Evidence of basal ganglia involvement in mask-induced inhibition	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
269	Abnormal Top-down Perceptual Modulation Drives Visual Hallucinations in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
270	Semantic Memory in Parkinson's Disease: Linguistic Features and Neural Correlates	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
271	Blood Pressure Profile of PD-MCI and PDD in Parkinson's Disease Patients at Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia	Saturday, September 28	13:00-15:00	Parkinson's Disease: Cognitive functions
272	Mechanical and thermal thresholds in the MPTP macaque model of Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
273	The assessment of anxiety and depression comorbidities and the DRN electrophysiology in a primate model of Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
274	Investigating an Emerging Anxiety-like Phenotype in a Novel Bilateral Rodent Model of Parkinsonian Alpha-Synuclein Pathology	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
275	Dissecting Neural Circuits Regulating Sleep State Transitions in a Mouse Model of Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
276	A Nomogram Model for Predicting Malnutrition among Patients with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
277	Two parallel nigrostriatal subcircuits mediate the arousal effect of dopaminergic neurons in substantia nigra pars compacta	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
278	Dual Frequency Stimulation of the Subthalamic Nucleus Improves Emotional State in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
280	Non-motor Symptoms and Quality-of-life of People with Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
281	Contrasting Olfactory Perception in Parkinson's Disease: Impact of GBA1 Gene Mutations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
282	Exploring the Influence of Gastrointestinal Symptoms on Non-Motor Fluctuations in Parkinson's Disease: Insights from the ReMePark-2, a Mexican Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
283	Personality of Parkinson's disease patients may influence the development and evolution of non-motor fluctuations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
284	Transcutaneous tibial nerve stimulation for overactive bladder symptoms in Parkinson's disease: results from a phase II randomised control trial (STRIPE)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

285	Gender Disparities in Daytime Sleepiness Among Hispanic Individuals with Parkinson's Disease: A Cross-Sectional Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
286	Feasibility of a Web Application to Enable Social Interaction in the PREDICT-PD Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
287	Integrating Non-Motor Symptoms and Gender Variability in Machine Learning for Early Parkinson's Disease Detection	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
288	Behavior medicine perspectives in pre-DBS patients with ET and PD	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
289	Determinants of nocturnal arterial hypertension in Parkinson's disease patients in Cameroon	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
292	Comparative Effectiveness of Behavioral or Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
293	The Effect of an Exogenous Ketone Supplement on Gut Microbiota in Parkinson's disease, a Pilot Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
295	Effect of Orthostatic Hypotension Medications on Orthostatic Ratio: A Systemic Review and Meta-Analysis	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
296	Looking Away: Anxiety Interferes with the Ability of Freezers to Attend to Visual Cues	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
297	Dysphagia is Frequent in early Parkinson's Disease. Results from a 5-year Follow-up Study.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
298	A Network Analysis shows How Impulsive-Compulsive Behaviors correlates with Levodopa-Induced Dyskinesia	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
299	Odor-specific symptoms in Parkinson's disease – UPSIT odor identification status versus clinical severity.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
300	Gender-Based Differences in Sleep Quality Among Hispanic Parkinson's Disease Patients	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
301	Shifting Tides of Caffeine: Evaluating Consumption Patterns In Parkinson's disease Progression	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
302	Changes in slow-wave sleep characteristics in Parkinson's disease patients with depression	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

303	Perspective of people living with early Parkinson's Disease: most common, burdensome, and worrisome symptoms	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
304	Designing a Device for Real-time Monitoring and Digital Integration of Non-motor Symptoms	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
305	Episodes of Hypoglycemia in Patients with Parkinson's Disease - Results of Two-Week Continuous Glucose Monitoring	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
306	Autonomic Dysfunction in Parkinson's Disease Link with disease severity and other non-motor signs	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
307	Effect on Cognition and Affect in Patients with Deep Brain Stimulation for Parkinson's Disease from Low Socioeconomic Status	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
308	Brainstem Monoaminergic Degeneration, Cognition, and Autonomic Symptom Progression in Early Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
309	Association Between Motor Symptoms and Autonomic Dysfunction in De Novo Parkinson's Disease: Insights into the Role of the Gut-Brain Axis	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
310	Unwinding Anxiety: Feasibility and Effectiveness of App-Based Mindfulness Training for People with Anxiety and Parkinson's Disease: A Pilot Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
311	Postural Stability Relates to Autonomic Dysfunction in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
312	Prevalence and characteristics of anxiety in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
313	TRPV1: A Potential Therapeutic Target for Inflammation and Pain in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
314	Decoding Fatigue in Parkinson's Disease: Exploring Multifactorial Associations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
315	Untangling Bidirectional Influences of Somatic and Internalizing Symptoms among People with Parkinson's Disease: A Retrospective Cohort Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
316	Molecular Landscape of Gastrointestinal Dysfunctions in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
317	SCN9A Gene Variant in a PD Case with Refractory Dysesthesias	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
318	Comparison of Age, Cognitive, Autonomic, and Motor Testing between Serotonergic vs Idiopathic REM-Sleep Behavior Disorder	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

319	Speech features in Korean Parkinson's disease patients: A prospective cohort study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
320	Fatigue in Parkinson's Disease: Prevalence and Risk Factors	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
321	Orthostatic Hypotension : a Clinical Marker for the Body-First Subtype of Patients with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
323	Validation of the International Parkinson and Movement Disorder Society – Non-Motor Symptoms – Questionnaire (MDS-NMS-Q)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
324	Predicting prodromal Parkinson's disease with a deep learning algorithm using medical and prescription data	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
325	Prevalence of Autonomic Symptoms in Mexican Population with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
326	Evaluating the Impact of the Pain Self-Management Program in PD	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
327	Prospective and Controlled Glucocerebrosidase-related Parkinson's Disease Evaluation of Non-Motor Symptoms (PROGENS-PD)	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
328	Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO), A Novel Retinal Mitochondrial Biomarker For Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
329	The Association between Non-Motor Symptom Burden and Quality of Life in the Nigeria Parkinson Disease Research Network Registry	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
330	Association of Autonomic Symptoms with Motor Features of Parkinson's Disease in the Nigeria Parkinson's Disease Research Network Registry	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
331	Prodromal Parkinson's disease in the general population	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
332	Comparasion of Motor, Non-motor, Social Aspects between Women with Parkinson's Disease with and Without Sexual Dysfunction	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
333	Impairment of REM Sleep Architecture: A Potential Biomarker for Parkinson's Progression	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
334	When Off Can Cost Life: Myocardial Infarction Due to Spontaneous Coronary Dissection as a Catastrophic Manifestation in Advanced Parkinson's Disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
335	Prevalence of Non-Motor Symptoms in Patients with Parkinson Disease in a Tertiary Hospital in Santiago, Chile.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

336	Effects on Speech After the Use of Swallow Against Resistance Exercise Device in Parkinson's Disease Patients	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
337	Age of Onset and Non-Motor Symptoms in Early Parkinson's Disease: A Data-Analysis Study Based on the Fox Insight Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
338	Clinical and Neuroimaging Biomarker Predictors of Autonomic Dysfunction in Parkinson's Disease: A Study Using PPMI Data	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
339	Exploring Supervised and Real-World Mobility in People with Parkinson's Disease with and without Nocturnal Hypokinesia	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
340	Prevalence of Helicobacter Pylori Infection Among Nepalese Parkinson's Disease Patients and their Clinical Manifestations	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
341	Clinical correlates of apathy in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
342	Unveiling Parkinson's Disease Risk Factors in the European Population-Based HeBA Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
343	Parkinson's disease biomarkers in human olfactory cleft mucus	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
344	Nutritional Impact at 6 Months in Parkinson's Disease: Follow-Up Results	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
345	Comparison of Motor, Non-motor, Social Aspects between Men with Parkinson's Disease with and without Erectile Dysfunction	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
346	RBD Unmasked: LRRK2 and the Prodromal Path to Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
347	Prodromal RBD and the risk of cognitive impairment in Parkinson's disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
348	Mood and Apathy Outcomes after STN or GPi DBS for Parkinson's Disease: An Interim Report from the ADROIT NAPA Sub-study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
349	Comparison of Gastrointestinal Dysfunction in Early-onset and Late-onset Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
350	Uncovering Non-Motor Subtypes in Parkinson's Disease through Machine Learning	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
351	Interim Report of Quality of Life Outcomes After Deep Brain Stimulation for Parkinson's Disease from a Large Global Real-World Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

352	Constipation in Early-Onset Parkinson's Disease: frequency, time of onset and association with mortality	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
353	Gastrointestinal Dysbiosis and Clinical Outcomes in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
354	Nocturnal Bradykinesia is better detected using wearable sensors in Parkinson's disease compared to clinical outcome	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
355	Beyond constipation: gastrointestinal phenomena in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
356	Autonomic dysfunction and its impact on quality of life in Mexican people living with PD	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
357	The effect of Diabetes Mellitus and Cardiovascular disease on Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
358	Clinical Predictors of Impulse Control Disorders in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
359	The effect of comorbid chronic post-traumatic stress disorder in dream enactment behavior among veterans with Parkinson's disease and REM sleep behavior disorder	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
360	Behavioral health characteristics of pre-surgical Focused Ultrasound and Deep Brain Stimulation candidates	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
361	Deep learning-based Prediction of Visual Dysfunction in Parkinson's Disease from 31 Brain Regions of Interest using Quantitative Diffusion MRI	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
362	The Association of Pain with motor symptom severity in Parkinson's Disease: A secondary data analysis	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
363	Plasma NFL predicting fatigue conversion in early Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
364	Characteristics of vegetative disorders in Parkinson's disease patients with Covid-19	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
365	Aberrant connectivity in Resting-State Brain Networks Underlying Neuropsychiatric Symptoms in Prodromal Lewy Body Dementia.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
366	Association of insomnia with levodopa-related parameters in Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
367	Transcranial Magnetic Stimulation of Median Prefrontal Cortex Improves Orthostatic Hypotension in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms

368	Assessment of pain in people with Parkinson's disease: an exploratory survey of international nursing experiences	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
369	Examining the Effects of Deep Brain Stimulation on Speech in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
371	Patients with Parkinson's disease have frequently pincer nail deformity	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
372	Misinterpretation of Hypnagogic/hypnopompic Experiences as Hallucinations in Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
373	Criteria Defining Chronic Pain Associated with Parkinson Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
374	Detecting impulsivity through speech in patients with Parkinson's Disease: A principle proof study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
375	The Contribution of Cognitive and Affective Factors to Balance Control in People with Parkinson's Disease Attending an Outpatient Clinic	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
376	Influence of Fatigue in Parkinson's Disease on Variability of Gait Measures	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
377	Association Between Hypertension Timing and Clinical Variables in Parkinson's Disease: A Retrospective Analysis	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
378	Exploring the Influence of Sleep Disorders on Speech Intensity in Individual's with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
379	Subjective Sleep Quality and Pathological Sleepiness in Veterans with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
380	Longitudinal patterns of Anxiety and Depression in patients with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Non-Motor Symptoms
382	Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson's Disease Case Study with Concomitant Refractory Major Depressive Disorder	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
383	Exploring the Root of Cognitive Decline in People Living with Parkinson's Disease: An Analysis of MoCA Scores, Neuropsychiatric Symptoms, and Patient-Reported Outcomes	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
384	Reduced Thalamic Nuclei Volume May Contribute to Anxiety in Parkinson's Disease: a 7-Tesla MRI Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations

385	Dopamine Dysregulation in Parkinson's Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
386	Neuropathological Synergy in Cauda Equina Syndrome, Parkinson's Disease, And Depression: Breaking the Dysphoric Cycle	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
388	Gender Disparities in Depressive Symptoms among Hispanic Parkinson's Disease Patients: A Cross-Sectional Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
389	Gender-related Cognitive Disparities in Hispanic Patients with Parkinson's Disease: A Cross-Sectional Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
390	Comorbidity of schizophrenia and Parkinson's disease: a clinical case report	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
391	Modeling the Role of Parkinson's Disease-Specific Factors in Depression and Anxiety: Findings from MEX-PD Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
392	The relationship between dimensions of mental health and markers of Parkinson's disease risk in the UK Biobank	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
393	Suicide risk relationship with motor and non-motor symptoms in patients with Parkinson's disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
394	Obsessive-Compulsive Disorder Prevalence in Parkinson's Disease Caregivers	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
395	Neurophysiological Underpinnings of Apathy in Parkinson's Disease Versus Depressive Disorders: A Comparative Study	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
396	Listening to the Insight: The Underdiagnosis of Depression in People Living with Parkinson's Disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
397	Apathy in de novo Parkinson's disease improves after the first years with dopaminergic treatment.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
398	Characterizing Dopaminergic Correlates of Depression in Parkinson's Disease: The PPMI Cohort	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
399	Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
400	Psychotic features in patients with Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations

401	Assessing the Accuracy of Clinical features, CSF Dopamine Metabolites, and Striatal Binding Ratios for the Likelihood of Depression Over 10-year Follow Up in the PPMI Cohort.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
402	Safety of Pimavanserin for Parkinson's Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
403	Outcomes in Patients with Parkinsonism Treated for Acute Agitation with Intravenous Benzodiazepines Compared to Parenteral Antipsychotics While Inpatient	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
404	Dopamine agonist use and psychotic symptoms in patients with Parkinson's disease.	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
405	Two unusual cases of dopamine dysregulation syndrome in patients with Parkinson's disease	Saturday, September 28	13:00-15:00	Parkinson's Disease: Psychiatric Manifestations
406	Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
407	EEG Profiles in People with Functional Movement Disorders Before and After a Single Bout of Hatha Yoga and Moderate-vigorous Intensity Aerobic Exercise: A Protocol for a Pilot Feasibility Study	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
408	Distress Tolerance in Patients with Tremor Disorders	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
409	Outpatient Treatment of Functional Movement Disorders	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
410	Functional Motor Disorders in pediatrics: motor patterns and clinical correlates.	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
411	The comorbidity conundrum in functional movement disorder: How are FMD patients with additional other FND different?	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
412	Creating a Multi-institutional, Interdisciplinary Functional Neurological Disorder (FND) Clinic in an Urban Setting	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders

413	Cognitive load in a diagnostic electrophysiologic assessment of functional tremor.	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
414	Phenomenology of Functional Movement Disorders in Children	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
415	Increased Resting Anterior Hippocampus Metabolism and Hippocampus Subfields Structural Abnormalities in Functional Tremor Patients: FDG- PET Study and Volumetric MRI Study	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
416	The Role of Cortisol a Mediator in Influencing Cognitive Function	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
417	Case Report Functional Neurological Disorder as a Harbinger of Spinocerebellar Ataxia 8	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
418	Malignant Functional Movement Disorders in Children, Experience from a Tertiary Care Center	Saturday, September 28	13:00-15:00	Functional Movement Disorders / Psychogenic Movement Disorders
419	Drug-Induced Parkinsonism and Tardive Dyskinesia in Rats Chronically Treated with Haloperidol	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
420	The Neuroprotective Effects of Rolipram, a Selective Phosphodiesterase IV Inhibitor, on Parkinson's Disease in Rat Models: A Pharmacological Exploration in both In vivo and In vitro Settings	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
421	GPR30 agonists attenuate haloperidol-induced neurotoxicity in SH-SY5Y cells and adult zebrafish.	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
422	Ibudilast, a Phosphodiesterase Inhibitor, Alleviates Huntington's Disease Pathology through Neuroinflammation Modulation and Signaling Pathway Regulation in a Rat Model	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
423	Neuroprotective Efficacy of Ethanolic Extract from Amorphophallus Paeoniifolius Tuber Against Haloperidol-Induced Parkinson's Disease Model	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
425	Complete Resolution of Tardive Dystonia After Bilateral Globus Pallidus Interna Deep Brain Stimulation	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
426	Reversing the irreversible: The application of Deep Brain Stimulation in The Syndrome of Irreversible Lithium Effectuated Neurotoxicity.	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders

427	Craniofacial Myoclonus: A Disabling Complication of Amantadine Therapy	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
428	Drug-induced tremors: A scoping review to assess knowledge gaps, controversies, and future directions	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
429	Quantitative EEG Analysis for Comparing Drug-Induced Parkinsonism and Parkinson's Disease	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
431	Bistriatal hypermetabolism on 18-FDG PET-CT in tardive dyskinesia	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
432	Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
433	Acute dystonic dyskinesias in a patient used fluvoxamine. Case report	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
434	Central Tremor after CAR-T Cell Therapy: A Case with Neurophysiologic Characterization	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
435	Case Report: Carbamazepine-Induced Dystonia, Tremor and Negative Myoclonus	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
436	Response inhibition in patients with Lithium induced Tremor	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
437	Prevalence of Movement Disorders in Epilepsy Patients Taking Antiepileptics Drugs in a Tertiary Care Teaching Hospital in Nepal.	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
438	Comorbid Tardive Dyskinesia (TD) and Restless Leg Syndrome (RLS)	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
439	Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
440	Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
441	A Rare Manifestation of Oculogyric Crisis in Schizophrenia Patients with Risperidone: Case Series	Saturday, September 28	13:00-15:00	Drug-Induced Movement Disorders
442	Systematic Review and Meta-Analysis of Pesticide Exposure and the Risk of Parkinson's Disease	Saturday, September 28	13:00-15:00	Epidemiology
443	Prognostic Value of Parkinson's Disease Subtypes in the LABS-PD Cohort: Functional ability, Quality of life and Mortality	Saturday, September 28	13:00-15:00	Epidemiology

444	Validation of PD Ascertainment in the VA Electronic Medical Record (EMR)	Saturday, September 28	13:00-15:00	Epidemiology
445	Prevalence of Cognitive Disorders and Other Features of Parkinson's Disease in Kyrgyz Republic	Saturday, September 28	13:00-15:00	Epidemiology
447	Characteristics of Parkinson's disease and associated healthcare resource utilization trends in a US all-payer health administrative claims database	Saturday, September 28	13:00-15:00	Epidemiology
448	Environmental Factors are Associated with Disease Severity of LRRK2 Related Parkinson's Disease and Idiopathic Parkinson's Disease: a Longitudinal Study	Saturday, September 28	13:00-15:00	Epidemiology
449	Clinical and epidemiological profile of Parkinson's disease in India	Saturday, September 28	13:00-15:00	Epidemiology
450	Rural Tanzania's Wide "PD Gap" Through the Decades	Saturday, September 28	13:00-15:00	Epidemiology
451	Changes in Parkinson's Disease and Parkinsonian Syndromes A Comparative Retrospective Study in Kyrgyzstan	Saturday, September 28	13:00-15:00	Epidemiology
452	Prevalence of Tic Disorder in School Children of Northern India	Saturday, September 28	13:00-15:00	Epidemiology
453	Baseline NSD-ISS stage predicts long term progression and survival in sporadic PD: 10-year PPMI data analysis	Saturday, September 28	13:00-15:00	Epidemiology
454	Predicting the Risk of Parkinson's Disease by Body Composition and Metabolic Diseases in Gender and Age Dependent Manners	Saturday, September 28	13:00-15:00	Epidemiology
455	Systematic Review of Incidence and Prevalence Studies of Multiple System Atrophy	Saturday, September 28	13:00-15:00	Epidemiology
456	Parkinson's Disease Burden in Underserved Populations Across the US in 2022	Saturday, September 28	13:00-15:00	Epidemiology
457	PD in Tanzania: representative in city dwellers, absent in nomadic tribespeople?	Saturday, September 28	13:00-15:00	Epidemiology
458	Prevalence and Spectrum of Movement Disorders in a Rural Neurology Clinic in Western India	Saturday, September 28	13:00-15:00	Epidemiology
459	PREVENT-PD: A Framework for Collecting Trichloroethylene Contamination Data in New York State	Saturday, September 28	13:00-15:00	Epidemiology
460	Incidence and Prevalence of Parkinson's Disease Among United States Medicare Beneficiaries by Age, Sex, Race/Ethnicity, and Neighborhood Socioeconomic Status 2014-2021	Saturday, September 28	13:00-15:00	Epidemiology

461	Prevalence of Advanced Parkinson's Disease and Potential Candidacy for Device-Aided Therapies in the Casablanca Region: Preliminary Results of a Multicenter Regional Study	Saturday, September 28	13:00-15:00	Epidemiology
462	12 year gap analysis in Parkinson's Disease mortality in Brazil	Saturday, September 28	13:00-15:00	Epidemiology
463	Parkinson's disease in Brazil: prevalence and patient characteristics in a nationwide representative population-based cohort.	Saturday, September 28	13:00-15:00	Epidemiology
464	Profile of patients affected by movement disorders in subspecialized outpatient clinics of a tertiary hospital in Southern Brazil	Saturday, September 28	13:00-15:00	Epidemiology
465	Long-term Blood Pressure Measures in Incident Parkinson's Disease in the Framingham Heart Study.	Saturday, September 28	13:00-15:00	Epidemiology
466	Association between Non-Motor Parkinson's disease symptoms and hyposmia in a population-based cohort	Saturday, September 28	13:00-15:00	Epidemiology
467	Motor and Non-Motor Characteristics of Parkinson's Disease in a Prevalent Population in Tanzania	Saturday, September 28	13:00-15:00	Epidemiology
468	Gender Differences in Physical Activity in Parkinson's Disease	Saturday, September 28	13:00-15:00	Epidemiology
469	Exploratory Cross-Sectional Analysis of Lifestyle and Parkinson's Disease Symptomatology	Saturday, September 28	13:00-15:00	Epidemiology
470	Association between Dipeptidyl Peptidase-4 Inhibitor Usage and Mortality in Parkinson's Disease: a nation-wide study	Saturday, September 28	13:00-15:00	Epidemiology
471	Clinical characteristics of movement disorders associated with multiple sclerosis patients: A cross sectional preliminary single center results.	Saturday, September 28	13:00-15:00	Epidemiology
472	Trend-Analysis of Movement Disorders, Malignant Neoplasms and Mortality from 1999-2020	Saturday, September 28	13:00-15:00	Epidemiology
473	Abstract: Trends in Movement Disorders related death in the United States from 1999 to 2020	Saturday, September 28	13:00-15:00	Epidemiology
474	Disparities in Botulinum Toxin Utilization for Cervical Dystonia in a United States Medicare Population	Saturday, September 28	13:00-15:00	Epidemiology
475	Global Trend of Parkinson's Disease in 38 OECD Countries from 1990-2019: An Insight from the GBD 2019.	Saturday, September 28	13:00-15:00	Epidemiology

476	Spectrum of Movement Disorders in Kazakhstan: Five Years of Insights from Kazakhstan's First Movement Disorder Center	Saturday, September 28	13:00-15:00	Epidemiology
477	No Association between Anemia and Risk of Parkinson's Disease: Evidence From A Meta-Analysis Using Real-World Evidence	Saturday, September 28	13:00-15:00	Epidemiology
478	Prodromal and overt Parkinson's Disease Epidemiological Study in Brazil (PROBE-PD study): preliminary results	Saturday, September 28	13:00-15:00	Epidemiology
479	Clinical profile of early-onset Parkinson's disease	Saturday, September 28	13:00-15:00	Epidemiology
480	Cohort effects on risk scores and risk markers for Parkinson's disease – comparison of an online-recruited versus population-based cohort	Saturday, September 28	13:00-15:00	Epidemiology
481	Non-Motor Symptoms and Comorbidities in a Cohort of Puerto Rican Parkinson's Disease: Do They Affect Severity and Progression?	Saturday, September 28	13:00-15:00	Epidemiology
485	Conceptualization of the MDS Parkinson's Disease Psychosis Rating Scale (MDS-PDRS) prototype.	Saturday, September 28	13:00-15:00	Rating Scales
486	Implementation of the Parkinson's Disease-Health Index (PD-HI), a Novel, Validated, Disease-Specific Patient-Reported Outcome Measure, in a 24-Month Natural History Study	Saturday, September 28	13:00-15:00	Rating Scales
487	Time To Rethink the Measurement of Tremor in Early-Stage Parkinson's Disease	Saturday, September 28	13:00-15:00	Rating Scales
488	Longitudinal Analysis of fragile X-associated tremor/ataxia syndrome Progression: A One-Year Follow-Up of 24 Patients	Saturday, September 28	13:00-15:00	Rating Scales
489	Correlation of Clinical Rating Scale for Tremor with Global Assessment	Saturday, September 28	13:00-15:00	Rating Scales
490	Reliability and Validity of the English Version of the Parkinson Anxiety Scale	Saturday, September 28	13:00-15:00	Rating Scales
491	Validation of the Kazakh Version of the Movement Disorder Society-Unified Dyskinesia Rating Scale.	Saturday, September 28	13:00-15:00	Rating Scales
492	Monitoring Progress: Use of the Behavioral Dyscontrol Scale-2 (BDS-2) in FXTAS (Fragile X-associated Tremor Ataxia Syndrome) Progression	Saturday, September 28	13:00-15:00	Rating Scales
493	Validation Study of the Parkinson's Disease Stigma Questionnaire (PDStigmaQuest)	Saturday, September 28	13:00-15:00	Rating Scales
494	Movement Disorder Society Unified Parkinson's Disease Rating Scale Motor Examination Retains Its 2-Domain Profile in Both On and Off States	Saturday, September 28	13:00-15:00	Rating Scales

496	Depression and Cognitive Phenotype in Idiopathic Parkinson's Disease without Dementia (IPDWD). Preliminary Results of a Comparative Study of a New Scale ESDEPARK Assessing Depressive Symptomatology Specifically in IPDWD vs a General Geriatric Depression Scale.	Saturday, September 28	13:00-15:00	Rating Scales
497	Depressive Symptomatology and Neuropsychiatric Profile in Patients with Idiopathic Parkinson's Disease without Dementia (IPDWD). Preliminary Data from a New Scale Specifically for Measuring Depression in Patients with IPDWD.	Saturday, September 28	13:00-15:00	Rating Scales
498	Visuospatial-Visuoconstructive Alterations and Depressive Symptomatology in Patients with Idiopathic Parkinson's Disease without Dementia (IPDWD). Preliminary Data from a New Scale Specifically for Measuring Depression in Patients with IPDWD.	Saturday, September 28	13:00-15:00	Rating Scales
499	Self-perception of Health and Depressive Symptomatology in Patients with Idiopathic Parkinson's Disease without Dementia (IPDWD). Preliminary Data from a New Scale Specifically for Measuring Depression in Patients with IPDWD.	Saturday, September 28	13:00-15:00	Rating Scales
500	Split-belt Treadmill Training to Rehabilitate Freezing of Gait and Balance in Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
501	Interim Analysis of the Feasibility of Mediterranean-Ketogenic Dietary Interventions in Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
502	Exploring feasibility and efficacy of a ballet-based intervention in advanced Parkinson's disease.	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
503	Exercise for Parkinson's: Building a Person-centered Resource through Partnership	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
504	Enhancing Real-Life Gait Performance in Persons with Parkinson Disease through the Music-Based BeatWalk Application	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
505	Therapeutic effects of PNF techniques versus standard physiotherapy exercise on diaphragmatic muscle activity in in the treatment young onsets of Parkinsons survivors	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
506	The Effect of Genotype on Voice & Swallowing in Parkinson's Disease: A Parkinson's Progression Markers Initiative Study	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation

508	Pump Priming a Parkinson's Rapid Response Physiotherapy and Occupational Therapy Service	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
509	Intelligent Assessment of Abnormal Movements in Neurological Disorders: An Update	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
510	Development of a National Initiative for the Professionalization of Parkinson Nurses - Results from Germany	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
511	Quality Improvement of Careflow Referrals to Parkinson's Disease Nurse Specialist (PDNS) Service at East Kent Hospitals University Foundation Trust (EKHUFT)	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
512	Touchscreen performance in people with Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
514	Responders to a Highly Challenging Balance and Gait Intervention in People with Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
515	Exploring the Feasibility of Telerehabilitation for Balance Deficits in People with PD; the TelePD Trial	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
516	An Investigation of Quality of Life for Caretakers of Parkinson's Disease Patients in Indian Villages	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
517	Integrated management of persons with Parkinsonism: a new model of patient-centered healthcare at home coordinated by a Case Manager via Telenursing.	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
518	An Analysis of Baseline Measures from a Diverse Parkinson's Disease Interdisciplinary Clinic	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
519	PreActive-PD Telehealth Coaching to Increase Physical Activity in Early-Stage Parkinson Disease: A Randomized Controlled Feasibility Trial	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
520	Feasibility and Preliminary Efficacy of a Pilot Telehealth Physical Activity Intervention in Degenerative Cerebellar Disease (Engage-Ataxia)	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation

521	Is fatigue a rate limiting factor for achieving motor learning and functional gains in people with spinocerebellar ataxia? (PRIME-Ataxia RCT)	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
522	Role of Wearable Devices in a Physical Activity Coaching Program for People with Parkinson Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
523	A telehealth physical activity coaching program can maintain physical activity and exercise confidence in people with Parkinson disease: a cohort study.	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
524	Utility of Instrumented Timed Up and Go Test to Estimate Disease Severity in Huntington Disease.	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
525	Revitalizing Lives: The Dystonia Care Rehabilitation Program	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
526	Intensive Neurophysiological Rehabilitation System As a New Approach for Treatment of ASD Children	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
527	Functional Changes Occuring During 10-Week Parkinson's Disease Group Fitness Classes and Subsequent 8-Week Break	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
528	MOVE-PD: Mapping the Correlation of Sedentary behavior with Motor Symptoms in Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
529	Virtual reality in patients with Hereditary Spastic Paraplegia	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
530	Balance evaluation and vestibular rehabilitation in patients with Hereditary Spastic Paraplegia - randomized clinical trial	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
531	Hand and Arm Function in Persons with De Novo Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
532	Use of Personalized Musical Cues to Optimize Walking in People With (and Without) Parkinson Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation

534	The Prospect of Exoskeletons for Individuals with Parkinson's Disease: A Comprehensive Review	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
535	Cross-sectional study: what is the sleep quality, daytime sleepiness and quality of life like of people with parkinson's disease at different stages of the disease?	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
536	Can Simple Home Based Exercises Reduce the Fear of Falling in Parkinson Disorders?	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
538	A Systematic Review of Action Observation Therapy for Parkinson's Disease Rehabilitation	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
539	Masticatory function evaluation methods in movement disorders	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
541	Long-term Physical Exercise on Bone Mineral Density, Balance and Gait in Older Adults with Mild to Moderate Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
542	Acute effects of a multicomponent aquatic training session on heart rate variability in PD: a case study	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
543	An Innovative Approach Combining Transcranial Direct Current Stimulation and Speech Therapy for the Treatment of Dysphagia in Parkinson's Disease.	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
544	Effects of Telerehabilitation on Balance, Gait, Functional Mobility, Physical Activity, Quality of Life, and Social Support Among Adults with Parkinson Disease: A Systematic Review	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
545	Cross-cultural adaptation to Argentine Spanish and validation of the High Level Mobility Assessment Tool in individuals with Parkinson's disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
546	Correlation between specific lower limb muscle strength and postural instability and gait difficulties in Parkinson's disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
548	The Spatiotemporal Characteristics of Floor Sitting Rising in Parkinson's Disease (PD)	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation

549	ProACT Study Protocol: a Randomized, Wait-list Controlled, Pragmatic Study on Parkinson's Disease Multimodal Complex Treatment	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
550	Alexander technique remote-delivery group course for people living with Parkinson's improves motor plan assembly time with correlated improvement in function	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
551	Does cannabis increase one's risk for a fall in Parkinson's disease?: cross-sectional analysis of self-report balance problems and freezing of gait	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
553	Comparison Between the 2MWT and the 6MWT as Measures of Walking Capacity in Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
554	Evaluating Fall Risk in People with Parkinson's Disease Using a Novel Comprehensive Posturography Assessment	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
555	Cohort study and Review on Physiotherapy in the Rehabilitation and Pro-longed Bed Rest of Atypical Parkinsonism's Syndrome Patients	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
556	Speaking Out for Speech Therapy: Referral Patterns and Disparities in PD	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
557	The role of cognitive functions on the outcomes of an intensive multidisciplinary rehabilitation program for people with Parkinson's disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
558	The neural contributions to fear of falling avoidance behavior in Parkinson's disease: preliminary evidence from a mobile neuroimaging paradigm	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
559	Augmented feedback during virtual reality training improves learning in people with Parkinson's disease: A Single-Blind Randomized Clinical Trial	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
560	Could Augmented Reality With Biofeedback Be Beneficial In Improvement Of Motor And Non-motor Symptoms In Patients With Parkinson's Disease?	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
562	Exploring the Impact of Mechanoacoustic Vibration Therapy on Mobility, Bone Density, and Postural Stability in Perimenopause Women with Huntington's disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation

563	Impact of Community Boxing Program on Non-motor Symptoms in Individuals with Parkinson's Disease	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
564	Evaluation of Effectiveness of Medical Nutrition Therapy Services for Individuals with Parkinson's Disease: A Quality Improvement Initiative	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
565	The Freezing of Gait Change of Direction (FOG-COD) Test: A Novel Measure to Predict Falls	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
566	Patient-developed Unique Methods to Overcome Freezing of Gait in Parkinsonian Disorders	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
567	Breaking Barriers to Offer Evidence-Based Services for Patients with Parkinson's Disease in South Africa	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
568	Possible Sarcopenia and its Association with Physical Activity among Parkinson's disease Patients	Saturday, September 28	13:00-15:00	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation
578	Perceptions of Diseases in Patients with Cervical Dystonia	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
579	Developing a Virtual Brick-Building Group for Veterans with Movement Disorders	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
580	Uncovering Patient Perspectives on Parkinson's Disease to Inform Individualized Care	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
581	Prevalence of non-motor symptoms and their impact in quality of life in PD: a Mexican Registry, 2011-2019 (the ReMePark-2 study).	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
582	Parkinson's Disease Clinical Subtypes Differ in Health-Related QOL	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
583	International Perspectives of Care Partners for People with Parkinson's Disease	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders

584	The Impact of Apathy and Impulsivity on Caregivers in Atypical Parkinsonian Syndromes	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
585	What assistive devices do people with Parkinson's disease find most useful?	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
586	Gender Disparities in Quality of Life Domains Among Hispanic Individuals with Parkinson's Disease: A Comparative Analysis	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
587	Stigmatizing Attitudes Towards People With PD Using The Parkinson's Disease Social Stigma Perception Scale (PDSP): A Nationwide Study	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
588	Loneliness Relates to Gait Over Other Features of Parkinsonism	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
589	State of happiness as outcome measure in sleep disorders in Parkinson's disease	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
590	Development and Feasibility Trial of iSupport-PD, a Digital intervention for carers of people with Parkinson's and Cognitive Impairment	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
591	Minimally Clinical Important Differences of Hemifacial Spasm Score-30 (HFS-30) and Hemifacial Spasm Score-7 (HFS-7) for Patients with Hemifacial spasm	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
592	Quality of Life in Parkinson's Disease Patients with Sleep Disturbances	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
593	The Impact of Deep Brain Stimulation on the Embarrassment and Self-Esteem of Patients with Essential Tremor	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
594	'If you can't beat them, join them': a patient and family perspective on quality of life with North Sea progressive myoclonus epilepsy	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
595	A Novel Peer Mentoring Support System for Persons with Parkinson's Disease	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders

596	Incidence of Depression in the Caregivers of Parkinson's Disease Patients	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
597	Transforming Parkinson's Care in Africa: Establishing the First Ever Support Group for People With Parkinson's Disease and Their Caregivers in Tanzania.	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
598	Transforming Parkinson's Care in Africa: Establishing a Global Virtual Support Group for Africans Impacted by Parkinson's Disease	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
599	Quality of life assessment in patients with Parkinson's disease	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
600	Parkinson's Disease (PD) and predictors of Driving Cessation: Results from a 6-year Longitudinal Study and a systematic review of the literature	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
601	The bypassing and embedded PEG J	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
602	Deep Brain Stimulation From the Perspective of Relatives and Caregivers: A Qualitative Analysis and Caregiver Burden	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
603	"Quality of Life of Caregivers Living with a Movement Disorder. A Comprehensive Approach."	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
604	Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia	Saturday, September 28	13:00-15:00	Quality Of Life/Caregiver Burden in Movement Disorders
606	Salford's Community Based Movement Disorder Service: Providing integrated care for people in their own homes.	Saturday, September 28	13:00-15:00	Palliative Care
607	Predictors of Death within 6 Months in Individuals with Dementia with Lewy Bodies	Saturday, September 28	13:00-15:00	Palliative Care
608	Developing a Supportive Care and Wellness Program for Parkinson's Patients	Saturday, September 28	13:00-15:00	Palliative Care
609	Health Care Utilization at the End-Of-Life in Parkinson's Disease	Saturday, September 28	13:00-15:00	Palliative Care

610	The AIMS Clinic Model: A Retrospective Analysis of Interdisciplinary Neuropalliative Care for People with Advanced Parkinsonism	Saturday, September 28	13:00-15:00	Palliative Care
611	Lumbar Punctures in Parkinson's Research	Saturday, September 28	13:00-15:00	Patient Perspectives
612	Experiences of a personalised intervention to support self-management in PwP - PD-Care: Live Well with Parkinson's	Saturday, September 28	13:00-15:00	Patient Perspectives
613	Gathering Prodromal Participant Perspective on Receiving Personal Research Information	Saturday, September 28	13:00-15:00	Patient Perspectives
614	WATCH-PD Qualitative Study: A Mental Model of Coping with Disease Progression	Saturday, September 28	13:00-15:00	Patient Perspectives
615	Combining MDS-UPDRS Parts 1 and 2: using the patient's voice	Saturday, September 28	13:00-15:00	Patient Perspectives
616	Patient and Caregiver Experiences with Huntington Disease: Emotions, Challenges, and Unmet Needs in the Patient Journey	Saturday, September 28	13:00-15:00	Patient Perspectives
617	Experiencing Life with Tourette Syndrome: The Invisible Effects of Tics	Saturday, September 28	13:00-15:00	Patient Perspectives
618	Evaluation of Functional Impairment and Treatment Satisfaction in Patients With Essential Tremor: a Cross-Sectional Study of Physicians Using Real-World Data	Saturday, September 28	13:00-15:00	Patient Perspectives
619	Participant-reported personal utility of genetic testing for Parkinson's disease and interest in clinical trial participation	Saturday, September 28	13:00-15:00	Patient Perspectives
620	The development of an electronic motor symptoms diary for Parkinson's disease using qualitative patient insights	Saturday, September 28	13:00-15:00	Patient Perspectives
621	eHealth Technologies for People with Parkinson's: Acceptance & Implications	Saturday, September 28	13:00-15:00	Patient Perspectives
622	Palliative and end-of-life care in Parkinson's disease : French patients' perceptions and knowledge	Saturday, September 28	13:00-15:00	Patient Perspectives
623	Unmet Motor and Nonmotor Needs of People with Parkinson's in the Final Year of Life	Saturday, September 28	13:00-15:00	Patient Perspectives
624	Assessing Barriers to Advance Care Planning in Parkinson's Disease Within a Cuban-American Population	Saturday, September 28	13:00-15:00	Patient Perspectives
625	Patient Reported Outcomes of Using a Chaplain Service in a Huntington's Disease Clinic	Saturday, September 28	13:00-15:00	Patient Perspectives

626	SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
627	Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability—Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
628	Spectrum of Movement disorders, Imaging findings in SSPE and response to therapy – A prospective cohort study	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
629	Benefits of Exercise on Mobility, Balance, and Cognition in Community-Dwelling Older Adults: An On-Land vs. In-Water Comparison Study	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
630	Sympathetic Nervous System Overactivity in the Pre-Motor Stage of Parkinson’s Disease: Therapeutic Implications	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
631	Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
632	Ecopipam does not adversely affect Metabolic Parameters in Pediatric Subjects with Tourette Syndrome: Results from a Phase 2b with 12-month Open Label Extension Study	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
633	Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
635	Patient Characteristics and Real-World Use of Botulinum Toxins for Treatment of Chronic Sialorrhea	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
636	ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
637	Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
638	Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

639	A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
640	Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial - ISRCTN99462035.	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
641	Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
642	Clinical and Neurophysiological Response of Different Protocols of Non-Invasive Spinal Neuromodulation in Anti-Gad Positive Stiff Person Syndrome: A Case Report	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
643	A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
644	SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
645	Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
646	Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.	Sunday, September 29	13:00-15:00	Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
647	Analysis of Patellar Reflex in Parkinson Disease Patients after an Acupuncture Treatment Protocol – Case Series Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
648	Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): PDQ-39 Results from a Phase 3 Randomized Active-Controlled Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
649	Long-term evaluation of advanced Parkinson's disease burden and clinical outcomes: results from the PROSPECT observational study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
650	Nocturnal Use of Add-On Medications for Parkinson's Disease: Post Hoc Analysis of the COSMOS Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
651	Differential Symptom Cluster Responses and Predictors to Repetitive Transcranial Magnetic Stimulation Treatment in Parkinson's Disease : A Retrospective Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

652	Sleep disorders in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
653	Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
654	Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson's disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
655	Cervical percutaneous interferential current stimulation improves cough reflex and oral residue in patients with Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
656	Personality may influence the response to apomorphine infusion in Parkinson's disease patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
657	Correlation Between Sleep and Quality of Life in People With Parkinson's Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
658	Common and specific immediate effects in brain oscillations and motor symptoms of tDCS and tACS in Parkinson's disease: A randomized controlled trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
659	A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson's Disease (eCAP-PD): Technical and Design Considerations	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
660	Coordinated Reset Vibrotactile Therapy for the Treatment of Bradykinesia in Parkinson's Disease Patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
661	Inter- and intra-day variability in β -Glucocerebrosidase activity and pathway biomarkers in healthy volunteers and patients with Parkinson's disease with a GBA1 mutation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
662	Orthostatic hypotension in age-related neurodegenerative diseases: a bibliometric study from 2007 to 2023	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
663	Opicapone Effect on Sleep Disorders in Fluctuating Parkinson's Disease Patients: Findings from the OASIS Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
664	Gait Digital Outcomes Exploration from Continuous Real-World Recordings in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
665	Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
666	Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

667	Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson's Disease: the ISTRA ADJUST PD Randomized, Controlled Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
668	Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson's Disease (PD) Prevention	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
669	The relationship between pain threshold and striatal dopamine function in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
670	Opicapone as Add-on to Levodopa in Parkinson's Patients without Motor Complications: Preliminary Data from EPSILON	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
671	Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
672	A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
673	Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control - Real-World, USA Experience	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
674	Comparing digital gait and turning measures from a prescribed gait test in the clinic/laboratory versus the same test at home in people with Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
675	Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
676	Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
677	The Effect of Subjective Postural Vertical on Forward Flexed Posture in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
678	Characterisation of the Pattern of Daily Motor Fluctuations in Patients with Parkinson's Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
679	Efficacy of Opicapone and Levodopa with Different Levodopa Daily Doses in Parkinson's Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
680	Effect of Opicapone and Levodopa on Daily Motor Patterns in Parkinson's Disease Patients with Early Motor Fluctuations: Findings from the Korean ADOPTION Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

681	Effect of Opicapone and Levodopa on the Different Daily OFF Patterns in Patients with Parkinson's Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
682	REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
683	Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
684	Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
685	Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of PD and Experiences of Daily Living	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
686	Intrinsic Auricular Muscle Zone Stimulation for Moderate-to-Severe Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
687	Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson's Disease With and Without Care Partner Support	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
688	Impact of IPX203 on Parkinson's patients' motor states upon awakening: analysis of patient diary data	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
689	The 201 Trial in Untreated Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
690	Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
691	24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
692	AccessPD Registry Update: Accelerating Parkinson's Disease Research Through Integrated Digital Solutions	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
693	Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson's Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
694	Centralizing brain tissue donation for a large multi-site Parkinson's disease (PD) study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

695	Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
696	A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
697	Assessing a Video Based Approach at Measuring Parkinson's Disease Severity – A Validation Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
698	AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
699	Programming Adaptive Deep Brain Stimulation in the Clinic: Lessons from the ADAPT-PD Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
700	NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
701	Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson's Disease: A Longitudinal, Multi-Sensory Intervention Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
702	GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
703	WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson's Disease: Study Design and Status Update	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
704	The HIIT-Home4Parkinson's study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
705	Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's Disease: Interim Results From an Ongoing Open Label Extension	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
706	Identifying Subjects with Dopamine Transporter Deficit in a Population-based Recruitment Strategy: Kassel Data of Healthy Brain Ageing	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
707	Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson's Consortium	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
708	A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

709	Effects of Mental Practice on FOG in People with Parkinson's Disease: a Randomized Clinical Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
710	Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
711	Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
712	Motor Phenotype Changes over time in Parkinson's Disease. A 5-year Follow-up Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
713	Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
714	A Randomized, Double-Blind, Placebo-Controlled Trial of a Multi-Strain Probiotic for Anxiety in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
715	The Effect of Stochastic Resonance Stimulation in Neural Control of Balance During Walking in Parkinson Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
716	ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
717	Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson's: The EJS ACT-PD Experience	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
718	A Pilot Study of Intrajejunal Faecal Microbiota Transplant to Improve Motor Function in Patients with Parkinson's Disease Treated with Levodopa-carbidopa Intestinal Gel: Preliminary Findings.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
719	Retention Strategies in Parkinson's Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
720	Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
721	Parkinson's Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
722	Rationale and Design of the Slowing Parkinson's Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
723	Boosting Clinical Trial Power in Parkinson's Disease with AI-Generated Digital Twins	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

724	Estimating the Proportion of Parkinson's Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
725	Istradefylline effects on L-Dopa resistant tremor in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
726	A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
727	Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12-Week, Randomized Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
728	Developing a selection framework for digital measures of Parkinson's disease progression for the EJS ACT-PD trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
729	Safety and tolerability of opicapone in Parkinson's Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
730	Comparing Ring and Directional Globus Pallidus Stimulation Effects on Parkinson's Gait	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
731	Effect of Levodopa therapy in Hypokinetic Dysarthria in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
732	Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson's Disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
733	PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson's Disease through objective measurements and patient reported outcomes - a multicenter randomized controlled trial.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
734	Long-Term Evolution of Advanced Parkinson's Disease Burden: Subgroup Analysis from the 24 Month International PROSPECT Observational Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
735	Preliminary Efficacy of Bilateral Intraputaminial Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson's Disease: 18-Month Follow-Up From a Phase 1b Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
736	Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
737	Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
738	The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

739	Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
740	Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson's Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
741	Unraveling Plantar Pressure Dynamics in Parkinson's Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
742	LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson's disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
743	Incobotulinumtoxin A to Treat Sialorrhea in Parkinson's Disease: a Real-life Study: 5-year Interim Results	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
744	Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson's Disease (PD) Prevention.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
745	Remotely-deployed gamification intervention to increase physical activity in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
746	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease (PADOVA): Rationale, Design, and Baseline Data	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
747	Five-Year Changes in MDS-UPDRS-III after Light Treatment (Photobiomodulation)	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
748	Changes in Gut Microbiome of Parkinson's disease Patients using Photobiomodulation Therapy	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
749	Effect of Prasinezumab on Parkinson's Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
750	Meta-Analysis of Two Randomized Controlled Trials Assessing the Efficacy of Mesdopetam (IRL790) in Levodopa-Induced Dyskinesia in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
751	The Effects of Baduanjin on Fine Motor Skills in Mild and Moderate Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
752	Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

753	Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson's disease using targeted fructooligosaccharides: a double-blind, placebo-controlled, cross-over trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
755	Analgesic effect of electroacupuncture on Relieving pain in Parkinson's disease and the mechanism based on rs-fMRI	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
756	Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
757	Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
758	Adaptive vs Conventional Chronic Deep Brain Stimulation: Results from a Randomized Pilot Trial in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
759	Parkinson Patients` Motor and Cognitive Functions are Improved by High Intensity LSVT®BIG Physiotherapy - a Randomized Prospective Pilot Trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
760	Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
761	Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
762	First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α -synuclein mRNA for the Treatment of Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
763	Distinct pattern of synaptic loss in Parkinson's disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
764	The effects of DL-3-n-butylphthalide in patients with mild cognitive impairment due to Parkinson's disease: A multicenter, randomized, double-blind, placebo-controlled trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
765	Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson's Disease Patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
766	Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson's Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
767	Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials

768	Slow-SPEED-NL: Study Protocol for a Remote Trial of Exercise for Parkinson's disease Prevention	Sunday, September 29	13:00-15:00	Parkinson's Disease: Clinical Trials
774	Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat	Sunday, September 29	13:00-15:00	Neuropharmacology
775	Loganic Acid Alleviates the Bidirectional Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson's Disease	Sunday, September 29	13:00-15:00	Neuropharmacology
776	Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate	Sunday, September 29	13:00-15:00	Neuropharmacology
777	Characterisation of the pharmacokinetic profile of amantadine in the common marmoset	Sunday, September 29	13:00-15:00	Neuropharmacology
779	Neuroprotective Action of Betulin in Parkinson's disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model	Sunday, September 29	13:00-15:00	Neuropharmacology
780	Investigation of the Quantitative Impact of T-type Calcium Channels in Subthalamic Nucleus Neurons on Parkinson's Disease	Sunday, September 29	13:00-15:00	Neuropharmacology
784	Neuroprotective role of baicalein via autophagy mediated modulation of associated motor proteins in experimental animals of Parkinson disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
785	Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
786	Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson's Disease-Like Motor and non-motor Symptoms in Zebrafish	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
788	Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
789	Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson's Disease In-Vitro Models	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
790	The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson's Disease. A Quantitative Systems Pharmacology Approach.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
791	Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
792	Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson's disease rat model	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

793	Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
794	The challenge to prevent Parkinson's Disease with a new in vitro approach	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
795	Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
796	Evaluation of neuroprotective effects of doxycycline in a primate model of PD	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
797	TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson's disease models.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
798	Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
800	" Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain".	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
801	Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
802	Hesperidin lessens rotenone induced Parkinson diseases angiogenesis in nigrostriatal neuronal death through the AMPK/FOXO3 Signaling pathway	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
803	Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
804	Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
805	Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
806	Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
807	Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
808	In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca ²⁺ Channels in Subthalamic Neuronal Cells towards Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

809	A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
810	Trends in Physiotherapy Interventions and Medical Costs for Parkinson's Disease in South Korea, 2011–2020	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
811	Beta peaks as predictor for DBS outcome in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
812	Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
813	If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
814	Effect of Tactile Cueing on Dual Task Performance in Parkinson's Disease-A Systematic Review and Meta-Analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
815	The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
816	Attitudes and Beliefs Towards Medication Burden and Deprescribing in Parkinson Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
817	Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
818	Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
819	Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson's disease in the low-income country and environment of restricted medications.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
820	Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson's Disease Patients: A Systematic Review and Meta-analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
821	Bidirectional interplay between DBS and cognition in Parkinson's disease: a systematic review	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
822	Aerobic Exercise in Non-Exercisers with Advanced Parkinson's Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
823	An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

824	Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson's Disease: A Propensity Matched Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
825	Baseline Variables Associated with Apomorphine Sublingual Film Retention	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
826	Oropharyngeal Adverse Events in Parkinson's Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
827	Safety and Efficacy of Sublingual Apomorphine in Parkinson's Patients with or without Concomitant Dopamine Agonists Use	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
828	A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
829	Efficacy and Safety of Controlled-Release Levodopa in Parkinson's Disease: a Systematic Review and Meta-Analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
830	Adherence and Persistence Among Patients with Parkinson's Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
831	Exploring Non-Invasive Wearable Devices in Home Settings for Assessment and Treatment of the Duration of ON and OFF State and Freezing of Gait in Parkinson's Disease: A Case Study.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
832	Clinical benefit of Opicapone in patients with different Parkinson disease phenotypes. The OPTIMO study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
833	Relationships of blood Vitamin B12 and Homocysteine with Parkinson's Disease Progression in 3 Contemporary Clinical Trials	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
834	Nocturnal Hypertension in Parkinson's Disease. The Flip Side of a Tainted Coin	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
835	Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms-Capturing Geographical and Demographic Disparities in Parkinson's Disease Therapy Spanning Six Countries and Two Continents	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
836	Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
837	Motor Impact of Fasting in Parkinson's Disease Patients: An overview	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
838	AAV-mediated gene therapy for GBA-PD	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

839	Faecal Microbiota Transplant for Parkinson's Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
840	The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson's Disease and other Neurodegenerative Diseases	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
841	Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
842	Moderators of aerobic exercise effects on motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
843	Efficacy and Safety of Amantadine in Parkinson's Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
844	Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
845	Using Algorithm Guided Programming to Treat Parkinson's Disease Patients Implanted with Deep Brain Stimulation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
846	Characterising early morning akinesia and off (EMO) using Parkinson's kinetigraph: analysis from a two centre national database in Parkinson's disease .	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
847	The international validation of the "Stepped Care" toolkit for comprehensive real life clinical care: bridging massive unmet need in care of Parkinson's disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
848	Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
849	Efficacy of Audiovisual Neuromodulation in the Treatment of Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
850	Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
851	Recruitment of Ethn racially Diverse Participants for Disease-Modifying Drug Trials in Parkinson's Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
852	Indications of advanced therapies in Parkinson's Disease: a retrospective study in a Belgian reference center	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
853	Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

854	Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson's disease, from clinical trials to healthcare resource usage	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
855	Prediction of The Monopolar Review in Deep Brain Stimulation for Parkinson's Disease using Imaging	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
856	Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
857	One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
858	Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
859	Pregnancy in Parkinson's disease: Five cases	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
860	Long term evaluation of gluten-free diet in Parkinson's disease patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
861	Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
862	Gender Differences Following Bilateral STN DBS Surgery in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
863	Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
864	Opicapone Reduces Homocysteine Levels in Patients with Parkinson's Disease Treated with Levodopa Gel Infusion	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
865	Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson's Disease Patients in Colombia	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
866	Palliative Care in Advanced Parkinson's Disease: Descriptive Analysis and Symptom Impact	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
867	Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
868	Effects of GBA mutations in patients with Parkinson's disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre 'real-world' study.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

869	Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson's Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
870	Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson's Disease: A Single-Center Retrospective Chart Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
871	Effectiveness of Subthalamic nucleus (STN) Deep Brain Stimulation Surgery (DBS) in patients with Parkinson's Disease: A Patient and Caregiver reported outcome	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
872	Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
873	The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
874	A comprehensive at-home and in-hospital work-up of patients with Parkinson's disease receiving foslevodopa/foscarbidopa continuous subcutaneous infusion	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
875	Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson's disease: a two-year experience	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
876	Istradefylline therapy for dystonia in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
877	Identifying the Most Sensitive Patient-reported Items from the MDS-UPDRS that Predict Initiation of PD Medications in Early Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
878	Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson's Disease in the End-of-Life Period	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
879	Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
880	Writing rehabilitation in parkinson's disease (pd) through a virtual workshop	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
881	Association between statin use and mortality in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
882	A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
883	ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson's Disease and Radicular Pain	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy

884	Peri-Electrode Edema after Deep Brain Stimulation Implantation – Case Report and Literature Review	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
885	Case Report Increasing 'On-time' Using Mucuna pruriens Concomitantly with Traditional Levodopa/carbidopa Management	Sunday, September 29	13:00-15:00	Parkinson's Disease: Pharmacology and Therapy
888	Repurposing Anti-Gout Medications for the Treatment of Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
890	The Protective Role of Lysosomal Damage Response in Preventing α -Synuclein Propagation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
891	Studying digenic Parkinson's disease in a stem cell model carrying mutant p.N409S in the GBA1 gene and the homozygous deletion of exon 3 PARK2	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
892	Pathological Mechanisms Associated with Atrazine-Induced Parkinson's Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
893	The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
894	Rora deficiency aggravates dopamine neurons loss via reducing NAD ⁺ level in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
895	Preclinical Studies: Investigating Serum-Based Exosomal miRNAs in Prodromal Drug-Induced Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
896	The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
897	Neuronal Exosome based markers in Parkinson's Disease and Progressive Supranuclear Palsy	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
898	Role of RNA splicing in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease

899	Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson's Disease Model Mice	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
900	Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson's Disease: Via GSK-3 β / Nrf2/HO-1 Signaling Pathways	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
902	Understanding the neuroprotective mechanism of <i>ilex Paraguariensis</i> (Yerba mate) in a <i>Drosophila melanogaster</i> alpha-synuclein model of Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
903	Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
904	Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
905	<i>ilex Paraguariensis</i> (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
906	Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
907	Parkin regulates ER-mitochondria association through interaction with IP3R-Grp75-VDAC1	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
908	iPLA2 β controls ER-mitochondria tethering and Ca ²⁺ transfer in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
909	TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
910	A novel single-cell reporter identifies regulators of the endogenous PINK1-Parkin mitochondrial quality control pathway	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
911	Exploring the Therapeutic Target for Lewy Body Disease using <i>gba1</i> Knock-out Medaka	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease

912	Differences in Molecular and Ultrastructural profiles of astroglia and microglia in substantia nigra of two different mice strains in normal aging and experimental Parkinsonism	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
913	Interaction of GCase and ganglioside GM1 in the aggregation of α -Synuclein	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
914	Dysregulated Anti-Viral Response in LRRK2 Mice Following Infection with H1N1 Influenza Induces DA Neuron Loss in the SNpc.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
915	Melatonin Modulates NLRP3 Inflammasome Activation through TLR2 to Protect Against Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
916	Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
918	Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
919	Consistent downregulation of rarely reported antioxidant genes viz., GGL, TR, TrX, HO-1, GR, GS, in the mid brain regions among mice and Drosophila exposed to Parkinsonian toxins: Scope as early diagnostic markers	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
920	Investigating the pathogenesis of GBA1-associated Parkinson's disease using GBA1 isogenic iPSC lines	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
921	LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
922	Simulated Space Gravity Recapitulates Parkinson's Disease Pathology in Neural Cell Model	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
923	Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
924	Measures of Mitochondrial Function in Serum across the Parkinson's Disease Spectrum	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease

925	The role of LRRK2 in regulating microglial activity in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
926	Alpha-Synuclein and Mitochondria Quality Control in Parkinson's Disease: A Literature Review	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
927	Discriminating alpha-synuclein strains in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
928	Rationale for LRRK2 inhibition in sporadic Parkinson's disease and the LUMA trial	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
929	Exercise Mitigates DNA Methylation Changes at cg17274742 Associated with the Circadian Gene Variant PER2 rs2304672: A Biobank Analysis	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
930	LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
931	Serum levels of VEGF-C and ENDGLIN in Parkinson's disease and their clinical relevance	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
932	Genetic signatures stratify PwP into three subgroups with differing responses in two disease-modifying Phase 3 trials and indicate multiple disease biology pathways to Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
933	Single cell transcriptomics of peripheral blood mononuclear cells and associations with clinical outcomes in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
934	Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-wide Association Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
936	Transcriptomic and Proteomic Profiling for Effective Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
937	Sphingomyelinase Activity in Patients with Sporadic Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease

939	Insulin-like growth factor 2 and inflammatory response in Parkinson Disease: Potential predictor marker	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
940	Identification of Pre-Diagnostic Biomarkers for Parkinson's Disease from Plasma Proteome	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
941	Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
942	Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Signature in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
943	The functional and lipidome signature of GBA1 mutant dopaminergic neurons	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
944	Association of Retinol Binding Protein (RBP) and the Risk of Parkinson's disease (PD): A Narrative Literature Review	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
945	Polyamine pathways: a promising frontier for biomarkers and therapeutic targets in Parkinson's disease (PD)	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
946	Declining Lymphocyte Count and Lymphocyte-to-Neutrophil Ratio Following Parkinson's Disease Diagnosis.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
947	The role of extracellular vesicles in the progression of Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
948	Cross-Omics Clustering Identifies Common Molecular Patterns in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
949	LRRK2 I1371V Mutation: Unraveling Pathogenic Mechanisms in Dopaminergic Neurons via Membrane Fluidity & Calcium Dysregulation using PD Patient iPSCs	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
950	Age and Parkinson's disease: clinical and biomarkers profiling of younger and older patients	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease

951	Distinct Gut Microbiome in Parkinson's disease Based on the Presence of Premotor Rapid-Eye Movement Sleep Behavior Disorders: Exploring the Alpha-synuclein	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
952	Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Molecular Mechanisms of Disease
956	IGF2 Induce Neuroprotection in PD Preclinical Models by Modulation of Immune Response.	Sunday, September 29	13:00-15:00	Therapy in Movement Disorders: Gene and Cell-Based Therapies
957	PARKIN gene replacement by AAV-mediated gene delivery as a therapeutic modality for PARKIN-deficient early-onset familial Parkinson's disease	Sunday, September 29	13:00-15:00	Therapy in Movement Disorders: Gene and Cell-Based Therapies
958	Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α -syn) as a potential gene therapy for Synucleinopathies	Sunday, September 29	13:00-15:00	Therapy in Movement Disorders: Gene and Cell-Based Therapies
959	Safety and Tolerability of Bemdaneprocel in People With Parkinson's Disease: Results up to 24 Months From a Phase 1 Study	Sunday, September 29	13:00-15:00	Therapy in Movement Disorders: Gene and Cell-Based Therapies
960	Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson's Disease: Results up to 24 Months From a Phase 1 Study	Sunday, September 29	13:00-15:00	Therapy in Movement Disorders: Gene and Cell-Based Therapies
961	A Machine Learning Approach for Early Identification of Prodromal Parkinson's Disease	Sunday, September 29	13:00-15:00	Artificial Intelligence (AI) and Machine Learning
962	Diffusion MRI and Machine Learning Distinguish Alzheimer's Disease and Dementia with Lewy Bodies	Sunday, September 29	13:00-15:00	Artificial Intelligence (AI) and Machine Learning
963	Developing a Supervised Machine Learning Model for Long-Term Cognitive Status Prediction in Parkinson Disease	Sunday, September 29	13:00-15:00	Artificial Intelligence (AI) and Machine Learning
964	Machine Learning Model Comparison for Freezing of Gait Prediction in Advanced Parkinson's Disease Patients	Sunday, September 29	13:00-15:00	Artificial Intelligence (AI) and Machine Learning
965	Reaching Kinematics in Movement Disorder Patients Using an Open-Source Computer Vision Technology	Sunday, September 29	13:00-15:00	Artificial Intelligence (AI) and Machine Learning
966	A Visual Interpretation Algorithm for Assessing 18F-Florzolotau PET Scans in Progressive Supranuclear Palsy	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)

967	Key neural tracts involved in tau depositions and neurodegeneration as revealed by multimodal MRI and PET assays in progressive supranuclear palsy	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
968	Ultrasound of Spinal Fluid Dynamics in Headache and Vertigo Patients with Central Sensitization: Novel Biomarker	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
969	Cortical and Subcortical Brain Volume Changes in Idiopathic REM Sleep Disorder Subjects at Risk for Parkinson's Disease	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
970	Clinical features and brain [18F] FDG PET patterns in patients with progressive supranuclear palsy with and without ventricular dilatation	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
971	Higher Putamen Volume Asymmetry with Age-Preserved Volume in Isolated Adult-Onset Cervical Dystonia	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
972	Essential Tremor: The Relationship Between Hand Dominance and Tremor Severity by MVPA	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
973	Correlating Dysarthria with MRI Findings in Temporal Lobe Glioma: Impact of Steroid Therapy on Cerebral Edema	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
974	Pure Autonomic Failure As a Severe "Body-First Subtype" of Lewy Body Disease: A Multimodal Imaging Study of the Autonomic Nervous System	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
975	Neuroimaging Factors Differentially Associated with Pathology and Clinical Presentation	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
976	A Curious Case of Copper de-Compensation	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
977	Sub-insular enlarged perivascular spaces are associated with gait symptom severity and tap response in normal pressure hydrocephalus	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
979	Increased Brain-Age Gap Estimate (BrainAGE) in Neurological Wilson Disease	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
980	Exploring Quantitative Susceptibility Mapping in Wilson's Disease- A Prospective Cohort Study	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
981	Differentiating Progressive Supranuclear Palsy from Corticobasal Syndrome Using Cortical Diffusion MRI	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
982	Alterations of NAD metabolism in symptomatic and asymptomatic carriers of pathogenic GCH1 variant	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
983	The value of DaT SPECT in rare movement disorders: acquired diseases	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)

984	Value of DaTSPECT in rare movement disorders: neurodegenerative diseases	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
985	The dementia with Lewy bodies related metabolic brain pattern (DLBRP) - a multicentric validation	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
986	Frontal atrophy in progressive supranuclear palsy[PSP] -an universal feature along with midbrain atrophy?	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
987	Cortical activity during visually perturbed gait in older adults	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
988	The Next Move in Movement Disorders: Differentiating between Hyperkinetic Movement Disorders using [18F] FDG PET	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
989	A group of patients with multiple system atrophy (MSA) exhibit cardiac sympathetic dysfunction to the same extent as Parkinson's disease (PD).	Sunday, September 29	13:00-15:00	Neuroimaging (Non-PD)
990	Structural magnetic resonance imaging patterns reflect α -synuclein propagation in a model of Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
991	Hippocampal volume in Parkinson's Disease in south India	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
992	Mitochondrial Complex I Brain Imaging in Parkinson's Disease and Lewy Body Dementia	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
993	Hemiparkinsonism Induction with 6-OHDA in Primates Does Not Induce SN Hyperechogenicity.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
994	The Impact of Drug Interactions on the results of DAT-SPECT Imaging in a Specialty Movement Disorders Practice: A Retrospective Analysis of Outcomes	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
995	Association of Striatal Dopaminergic Depletion, Cerebral Perfusion, and Cognitive Outcome in Brain-first and Body-first Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
996	STN-DBS Frequency Effects in Parkinson's: An fMRI Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
997	Sex-Related Differences of Resting-State Brain Activity in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
998	White matter abnormalities in motor subtypes of Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
999	Accuracy of AI-driven automated diagnostic software analyzing Susceptibility Map-Weighted Imaging to Differentiate Neurodegenerative from Non-neurodegenerative Parkinsonism	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1001	Metabolic characteristics of brain network in patients with Parkinson's disease after Deep brain stimulation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1003	Increased Brain Free Water is Associated with Regional Gene Expression in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1004	Identification of Brain Atrophy Subtypes in Prodromal and Overt Synucleinopathies: A Multicenter Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1005	Early GBA-Related Parkinson's Disease has a Distinct Clinical Phenotype and Cholinergic Innervation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1006	Mapping the distribution of neurotransmitters to resting-state functional connectivity in patients with Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1007	Analysis of structural connectivity in relation to change in dopaminergic medication after 6 months of STN-DBS in Parkinson's disease - a pilot study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1008	Resting-State Network Alterations in Patients with Isolated REM Sleep Behavior Disorder and their Association with Clinical Symptoms	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1009	Quantification of Neuroinflammation and White Matter Injury in Parkinson Disease Using Diffusion Basis Spectrum Imaging	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1010	First in vivo evidence of the role of the noradrenergic system in olfactory dysfunction in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1011	A Kinematic and fMRI Study of the Neural Correlates of Bradykinesia in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1012	Use of Machine Learning for Identification of Parkinson's Disease and Mild Cognitive Impairment through Neuroimaging and Biofluid Biomarkers: A Study from the PPMI Cohort	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1013	MIBG Uptake in the Major Salivary Glands in Patients with Parkinson's Disease and Dementia with Lewy Bodies	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1014	Motion-robust high-resolution imaging of nigrosome-1 in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1015	Cortical morphometry and subcortical volumetry in motor subtypes of Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1016	Longitudinal change in brain function and structure related to plasma neurofilament light protein in early-stage Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1017	Whole-brain functional network signature reflecting conversion of isolated REM sleep behavior disorder	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1018	Neural Correlates of Dual Task Touchscreen Performance in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1019	Microstructural Changes in the Inferior Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1020	Clinical and Brain Morphological Characteristics of Early LRRK2-associated Parkinson Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1021	Habenular Structural Connectivity Changes in Parkinson's Disease: A 7T MRI Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1022	Connectivity Profile for Increased Apathy Following Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1023	Abnormal basal ganglia-related functional gradient in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1024	Synaptic Density Loss in Parkinson's Disease Independent of Age: Preliminary Findings using [18F]SynVesT-1 PET Tracer	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1025	Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson's Disease Severity and Progression	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1026	Associations Between Striatal Dopamine Transporter Binding and Motor Asymmetry In De Novo PD with and Without RBD	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1027	Decrease in Walking Ability with Increased Functional Connectivity between Multiple Brain Areas in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1028	Cerebrovascular Reactivity and Glymphatic Clearance in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1030	Dopamine Transporter Imaging as Monitoring Biomarker in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1031	MRI Predictive Marker of the Vestibular Galvanic Stimulation Effectiveness in the Postural Instability Treatment in Parkinson's Disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1032	the Degeneration of Locus Coeruleus and its Enhanced Causal Relationship to Neural Circuit in Parkinson's Tremor	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1033	Differential Diagnosis of Parkinsonism with 18F-FP-CIT PET using a Self-supervised Deep Learning Model	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1034	Investigating the Use of 18F-DOPA PET/CT to Improve Diagnosis and Clinical Management of Parkinson's Disease in South Australian Movement Disorder Clinics.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1035	Classification of Parkinson's disease using AI based on multi-modal brain MRI connectomics	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1036	Neurovascular Involvement in Parkinson's Disease Cognitive Impairment: A 4D Flow Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1037	Associations between Choroid Plexus and tau in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1038	Cerebral metabolic network in PLA2G6-associated parkinsonism	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1039	Dopamine transporter imaging to predict the risk of aspiration in patients with Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1040	Impact of Altered Cerebrovascular Reactivity on Midbrain Degeneration, Perfusion and White Matter	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1041	Comparison of Spontaneous Brain Activity in Distinguishing Parkinsonian Variant of Multiple System Atrophy from Parkinson's Disease at Early Stage	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1042	The Contribution of APOE4 Genotype on Structural MRI in Parkinson's Disease: A Study from the PPMI Cohort	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1043	Severity of Motor Symptoms Correlates with Asymmetric Changes in Globus Pallidus Internus and Caudate Nuclei in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1044	Automated Imaging Differentiation of Parkinsonism (AIDP): A Prospective 21-site Trial within the Parkinson's Study Group	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1045	Ultrasonography Markers in Prodromal Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1046	Parkinson's Disease-Related Pattern in isolated REM Sleep Behavior Disorder as a prodromal progression marker	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1047	Visual Hallucinations and Pareidolias Across the Lewy Body Disease Spectrum	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1048	From Images to Insights: Subtyping Parkinson's Disease Using Unsupervised Learning on MRI Data	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1049	Cholinergic brain vulnerabilities associate with diabetic comorbidity in Parkinson disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1050	Morphology and Functional Connectivity of the Basolateral Amygdala and Rapid Eye Movement Sleep Behavior Disorder	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1051	Evaluating the association between cognitive impairment and striatal VMAT2 binding using [18F]AV-133 PET in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1052	The 2-Minute Walking Test Predicts Aerobic Fitness, Motor Function, and Brain Health in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1053	Data-driven image-based subtyping and staging of neurodegeneration in Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1054	Longitudinal Structural and Functional Correlates of Progression in Isolated Rapid Eye Movement Sleep Behaviour Disorder	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1055	Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1056	Improved Quantification of DAT-SPECT significantly increases its Performance as an Imaging Biomarker in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1057	[18F]PR04.MZ PET CT as a clinical tool in the differential diagnosis of PD and other atypical parkinsonian syndromes in the first 5 years of symptoms	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1058	Effects of striatal dopamine depletion and altered brain metabolism on Parkinson's disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1059	Functional Connectivity Changes Associated with Interlimb Coordination Force Deficits in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1060	Inflammation Biomarkers and Free Water Fraction in the Cholinergic Forebrain System in Idiopathic Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1061	Refining and Understanding Causal Relationships between Brain Imaging-Derived Phenotypes and Parkinson's Disease: a Bidirectional Mendelian Randomization Study and Clinical Validation	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1062	Dopaminergic denervation and focal motor progression in early Parkinson's Disease: A 5-year longitudinal study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1063	Association Between Cerebral Glucose Metabolism and Amyloid Deposition in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1064	The alteration of GABA and glutamate in Parkinson's disease is related to motor executive dysfunction: a 7T-MRS study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1065	Enlarged Perivascular Spaces in the Temporal Lobe as a Predictor for Incident Dementia in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1066	AI based longitudinal changes in substantia nigra contrast and volume on neuromelanin MRI and its relation to clinical markers in a multi-site Parkinson's disease study.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1067	Serotonergic dysfunction and impulse control disorders in Parkinson's disease: a double-tracer PET study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1068	Reduced parietal and sensorimotor cortex recruitment during complex gait in Parkinson's disease patients with freezing of gait	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1069	Regional Brain Volume Differences Across PD Clinical Subtypes	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1070	Characterization of a Novel alpha-synuclein PET radiotracer, [18F]C05-05, in a PPMI Sub-study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1071	MRI Visible Perivascular Spaces are Associated with Disease Duration and Severity in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1072	Transcranial Sonography of the Substantia Nigra and Vagus Nerve Ultrasonography as Complementary Diagnosis for Parkinson's Disease.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1073	Characterizing levodopa-induced dyskinesias using multimodal neuroimaging, clinical and behavioral measures	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1074	Examination of how DaTscan Impacts Diagnosis in Parkinsonian Patients with and without Dopamine Receptor Blocking Agent Exposure	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1075	Mapping Cholinergic Signaling in Parkinson Disease Using [18F]VAT	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1076	Naturalistic walking in Parkinson's disease: Prefrontal cortex activity measured with functional near-infrared spectroscopy (fNIRS)	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1077	Assessment of Visual Field in Patients with Moderate-to-Severe Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1078	Frontal Lobe Cortical Thickness and Volumetric Analysis in Parkinson's Disease Based on Impulse Control Disorder	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1079	Predicting Freezing of Gait (FoG) in Parkinson's Disease from Conventional T1-Weighted MRI	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging

1080	Differences in regional activity levels between healthy controls, PD-nFOG, and PD-FOG as measured by ALFF and fALFF using resting-state fMRI.	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1081	Cardiac Mitochondrial Complex I Integrity Predicts Axial Symptom Severity in Parkinson's Disease	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1082	Altered Dynamic Functional Connectivity in Parkinson's Disease Individuals with Visual Hallucinations and Dysfunction	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1083	Sex Cerebral Vasoreactivity Differences in Parkinson's Disease: Uncovering the Tip of the Iceberg	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1084	Comparative Study of Whole-Brain Functional Connectivity Patterns in Parkinson's Disease and Essential Tremor: A Resting-State fMRI Study	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1085	The Feasibility of ICA in Parkinson's Disease fMRI	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1086	Deep learning-based Prediction of Gait Dysfunction in Parkinson's Disease using Quantitative Diffusion MRI from Brain Network Regions of Interest	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1087	Cerebral vasoreactivity in patients with Parkinson's disease and Diabetes Mellitus	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1088	Early changes in the locus coeruleus in mild cognitive impairment with Lewy bodies	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1089	Evaluation of Glymphatic System Function in Parkinson's disease patients using Diffusion MRI	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1090	Alterations in neural processes of cognitive control in asymptomatic heterozygous mutation carriers in the Parkin gene	Sunday, September 29	13:00-15:00	Parkinson's Disease: Neuroimaging
1092	Emergency pallidotomy in a patient with chorea paralytica in primary hypoparathyroidism	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1093	Cognitive Outcome in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Treated with Deep Brain Stimulation (DBS):Case Report	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1094	One-Year Outcomes of Multitarget Thalamic and Pallidal Deep Brain Stimulation in Unilateral Dystonia	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1095	Deep Brain Stimulation (DBS) Improves Parkinsonism Caused by Osmotic Demyelination Syndrome (ODS)	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1096	Pregnancy in Dystonia or Tourette's patients with DBS. Eleven New Cases and a Review of the Literature.	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders

1097	A Successful Case of Bilateral GPi Rescue DBS in Dystonic Tremor Following Tremor Re-emergence After Previous Bilateral PSA DBS Five Years Prior	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1098	Deep brain stimulation for severe dystonia associated with Wilson's disease: A prospective multicentre meta-analysis of Nof1 trials	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1099	Real-World Clinical and Safety Outcomes from a Prospective, Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1100	Sustained Effect of Posteroventral Pallidotomy for X-Linked Dystonia Parkinsonism	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1101	Impact on quality of life and nonmotor symptoms of unilateral magnetic resonance-guided focused ultrasounds (FUS) thalamotomy in patients with essential tremor.	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1102	Deep Brain Stimulation of bilateral ventral intermediate nucleus in a patient with spinocerebellar ataxia type 12	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1104	Safety and efficacy of bilateral magnetic resonance-guided focused ultrasounds (FUS) thalamotomy for refractory essential tremor.	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1105	Radiofrequency Lesioning for hemidystonia: a systematic review	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1106	Safety of staged bilateral MR-guided focused ultrasound thalamotomy for essential tremor	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1107	MR-guided focused ultrasound for essential tremor: exploratory analysis comparing unilateral and staged, bilateral thalamotomy	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1108	Protocol for Cerebellar Deep Brain Stimulation in Children and Young Adults with Dyskinetic Cerebral Palsy: Combined N-of-1 trials to Assess Safety and Efficacy	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1109	Botulinum Toxin and Deep Brain Stimulation in Dystonia	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1110	Treatment of Severe Tardive Syndrome with Pallidotomy: A Case Report	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1111	Clinical effectiveness and safety of staged-bilateral MRgFUS for treating essential tremor, a literature review	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1112	Is acute dystonia in a teenager psychogenic dystonia?	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1113	Predictive Value of Brain Structural Changes on Motor Outcomes Following VIM Thalamotomy in Essential Tremor: Preliminary Results	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders

1114	Parkinsonism after Internal Globus Pallidus Deep Brain Stimulation in Dystonia	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1115	Unveiling the Long-term Impact of Unilateral Vim DBS in Essential Tremor	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1116	Deep brain stimulation Intraoperative imaging: False errors in the era of artificial intelligence	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1117	Patient Experience during Automated Deep Brain Stimulation (DBS) Changing for Sleep (PEACe study)	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1118	A Double-blind, Randomized, Crossover Clinical Trial comparing VIM vs. PSA Deep Brain Stimulation for Disabling Essential Tremor	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1119	Deep brain stimulation of globus pallidus internus for monogenic dystonia	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1120	GNAO1-related Neurodevelopmental Disorder with Involuntary Movements Inducing a Dyskinetic Status	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1121	Acute Reversible Laughter with Globus Pallidus Interna Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1122	Vim DBS for Post-Stroke Tremor: A Case Report	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1123	Deep brain stimulation of bilateral ventral intermediate nucleus in patients with neuronal intranuclear inclusion disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1124	Raynaud's Phenomenon and Diaphoresis During Initial Programming of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Case Report	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1125	Intraoperative venous air embolism in the semi-sitting position in functional neurosurgery	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1126	Prolonged Positive Response: Subthalamic Nucleus as a Deep Brain Stimulation Target in X-linked Dystonia-Parkinsonism	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1127	The Characteristics and Management of Patients with Dystonia Referred for The Troubleshooting of Deep Brain Stimulation Therapy: A Single Center Experience	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1128	Holmes Tremor Treated with Pallidal Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1129	How Local Field Potential could improve GPi Deep Brain Stimulation programming in Tourette`s Syndrome – Case Report	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders

1130	Treatment of status dystonicus in children using pallidal deep brain stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Other Movement Disorders
1131	Gait Analysis in the 6-Hydroxydopamine Hemiparkinson Rat Model with Deep Brain Stimulation in the Subthalamic nucleus	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1132	Understanding the Neurochemical Basis of STN and GPI-DBS: A Human Microdialysis Study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1133	Safety and effectiveness of staged bilateral MR-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson's disease: study protocol	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1134	Clinical Trends and Clinician Perceptions Regarding Asleep and Awake DBS	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1135	Perceptions Regarding Asleep and Awake DBS Among Neurologists and Neurosurgeons	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1136	Clinical Trends in Asleep and Awake DBS in North America vs Europe	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1137	Predictive elements for unilateral prelemniscal radiations radiofrequency lesions: A novel surgical approach for alleviating motor symptoms in Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1138	Evoked Resonant Neural Activity Automates Field Shaping of Subthalamic Nucleus-Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1139	Assessment of Image-Guided Programming (IGP) in Bilateral STN and GPI Deep Brain Stimulation on Programming Time and Setting Outcomes	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1140	Is Neuropsychological Evaluation Needed to Assess DBS Candidacy in Essential Tremor?	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1141	Long-term effects of Deep Brain Stimulation on gait and postural control in Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1142	Is GPI DBS as effective to STN DBS for tremor control in Parkinson's disease?	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1143	Pooling Event-Related Potentials with Anatomy and Lead Localization in Subthalamic Deep Brain Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1144	The Impact of Bilateral STN- Deep Brain Stimulation on Motor Symptoms and Quality Of Life in Advanced Parkinson's Disease: A Single Center's Experience	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease

1145	Weight Changes After Deep Brain Stimulation for Parkinson's Disease in The Registry for the Advancement of DBS in Parkinson's Disease (RAD-PD)	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1146	Real-world Programming and Sensing from Adaptive Deep Brain Stimulation for Parkinson's Disease in Japan	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1147	Responsive morphometric fingerprints in deep brain stimulation for Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1148	Time To Access Deep Brain Stimulation Surgery for Movement Disorders: A Canadian Single Center Study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1149	Dopamine Dysregulation Syndrome Outcomes following Pallidal Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1150	Deposition of phosphorylated TDP-43 around the tip of deep brain stimulation leads	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1151	The impact of Deep Brain Stimulation for Parkinson's disease on Quality of Life	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1152	Comparison of two methods of deep brain stimulation lead reconstruction and their prediction capacities	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1153	Subthalamic Local Field Potential Monitoring in Parkinson's Disease during Epidural Electric Spinal Cord Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1154	Deep Brain Stimulation Complications in Parkinson's Disease Patients: A 15-year Single-Centre Review	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1155	Real-world Experiences of Image-guided Programming in Subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1156	Feasibility and added value of sensing feature in patients with chronic STN DBS for Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1157	Cluster Analysis of Stimulation-Induced Dysarthria Subtypes in People with Parkinson's Disease and Subthalamic Deep Brain Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1158	Unilateral MRgFUS subthalamotomy in Parkinson's disease: A prospective clinical study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1159	PD GENERation: A cross-sectional evaluation of cognitive complaints in Parkinson's disease (PD) patients according to GBA1 and DBS status	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1160	Do differences in risk aversion and perceived social support contribute to gender disparities in deep brain stimulation utilization in Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease

1161	Ethnic and Gender Disparities in Access to Deep Brain Stimulation: A Qualitative Exploration	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1162	Long-term follow up of unilateral deep brain stimulation for Parkinson's disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1163	Acute and chronic effects of deep brain stimulation on gait in patients with Parkinson's disease.	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1164	The Role of a Social Worker in a Deep Brain Stimulation Multidisciplinary Team	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1165	Clinical Correlation of Double Oscillatory Peaks in Parkinson's Disease with Deep Brain Stimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1166	Evaluation of the results of neuromodulation of the Subthalamic Nucleus (STN) in patients with Parkinson's Disease (PD) depending on the anesthesia used during stereotactic electrode implantation.	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1167	Using LEAD-DBS to Identify the Optimal DBS Electrode in the Abbott Infinity System	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1168	Effect of Target Selection on Mood, Pain, and Medications after DBS in PD	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1169	Surprising Somatotopy: Buccinator Dyskinesia (Orobuccal Popeye Sign) Induced by Subthalamic Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1170	Focused ultrasound subthalamotomy in early Parkinson's disease: three-year prospective follow-up	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1171	Clinical and Imaging Changes in Parkinson's Disease Patients Under Spinal Cord Stimulation: A Double Blinded Analysis	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1172	Levodopa response is an inadequate and often biased correlate of STN-DBS outcomes	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1173	Functional connectivity enhances prediction of STN DBS motor outcomes	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1175	Focused Ultrasound Thalamotomy for Tremor-Dominant Parkinson Disease – Ablation Volume and Dentatorubrothalamic Tract Overlap Does Not Predict Outcome	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1176	Longevity of Motor Benefit Achieved with Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) in a Single Center Cohort at the Decade Mark Post-Implantation.	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease

1177	Telemonitoring-assisted DBS Optimization For Parkinson's Disease Patients	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1178	Deep Brain Stimulation Surgery – Hurdles and Maladies!	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1179	Viability and Accuracy of Visual Estimation in Determining Directional Deep Brain Stimulation Lead Orientation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1180	A comparative study of focused ultrasound unilateral thalamotomy and subthalamotomy for medication refractory Parkinsonian tremor	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1181	Early Outcomes Support use of a Remote Cross-Border Surgical Centre for Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1182	Bilateral subthalamic nucleus deep brain stimulation as effective and sustained therapy in Juvenile Parkinson's disease due to PTPA gene mutations	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1183	Imaging-based Troubleshooting Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1184	Impact of DBS STN on motor symptoms, postural instability, QoL in PD patients from the Belarusian population	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1185	MRgFUS thalamotomy for tremor-predominant Parkinson's disease: a single-center prospective study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1186	The Challenges of Adaptive Deep Brain Stimulation: A Delphi Panel Study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1187	Tension Pneumocephalus as an acute complication of STN-DBS surgery	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1188	Is the new device Percept-Medtronic really helping clinicians identifying location of contacts within the STN in STN-DBS?	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1189	Clinically implemented sensing-based initial programming of deep brain stimulation for Parkinson's disease: a retrospective study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1190	Development of a Beta-sensing Pathway in Deep brain stimulation to optimise utility of Local field potential recordings using the Percept system. (Newcastle Beta-sensing Algorithm – NBA)	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1191	Image-guided Programming versus Conventional Programming in Deep Brain Stimulation: Comparative Study of a Parkinson's Disease Cohort and Subthalamic Neurostimulation	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease

1192	Risk Tolerance of Therapeutic Interventions in People with Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1193	Connectivity-Based Analysis of the Impact of GPi Deep Brain Stimulation on the Freezing of Gait in Parkinson's Disease	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1194	Unilateral Deep Brain Stimulation in Parkinson's Disease: Long-term Efficacy and Bilateral Symptom Progression	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1195	12-month long-term outcomes of adaptive DBS using LFP sensing technology	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1196	Automated Selection of Deep Brain Stimulation (DBS) Parameters for Parkinson's Disease (PD) Using Pallidal Local Field Potentials (LFP): A Prospective Pilot Study	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1197	Deep Brain Stimulation during pregnancy: A systematic review of the literature	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1198	Extended long-term follow-up focused ultrasound subthalamotomy in Parkinson's disease: five-year prospective experience	Sunday, September 29	13:00-15:00	Surgical Therapy: Parkinson's Disease
1202	The Current State of Wearable Device Use in Parkinson's Disease (A Survey of Individuals with Parkinson's and Specialist Clinicians)	Sunday, September 29	13:00-15:00	Technology
1203	Can Technology Improve Service Delivery and Patient Outcomes in a Parkinson's Speech and Language Therapy Clinic?	Sunday, September 29	13:00-15:00	Technology
1204	Video-based Machine Rating Model for MDS-UPDRS III in Parkinson's disease: A Proof-of-concept Pilot Study	Sunday, September 29	13:00-15:00	Technology
1205	A Conversational GPT Agent for Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1206	Performance of a Smartphone-based Oculomotor Test as a Diagnostic Tool for Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1207	Advancing Interpretability in Parkinson's Disease Voice Analysis: A Multilingual AI Approach	Sunday, September 29	13:00-15:00	Technology
1208	Artificial Intelligence and Visual Analysis of Movements in Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1210	Efficiency of AI-Based Service for Screening Diagnostics of Parkinson's Disease (Brainphone Project)	Sunday, September 29	13:00-15:00	Technology
1211	Smartwatch-Based Screening to Identify Candidates for Deep Brain Stimulation in Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology

1212	Study of Wearable Technology And Geo-Fencing Device for Quantification of Freezing of Gait And Sleep Pattern In Dystonia Patients In Gurugram City, India	Sunday, September 29	13:00-15:00	Technology
1213	Ultrasensitive detection of aggregated α -synuclein using quiescent seed amplification assay for the diagnosis of Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1214	MDS PD e-Diary – a New Patient-Centered Digital Tool for People with Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1215	Hierarchical Machine Learning Classification of Parkinsonian Disorders using Saccades	Sunday, September 29	13:00-15:00	Technology
1216	Evaluating Adaptive Devices to Assist Eating in Essential Tremor Patients: A Comparative Analysis	Sunday, September 29	13:00-15:00	Technology
1218	Model-Based Gait Outcomes to Track Parkinson's Disease Progression ?	Sunday, September 29	13:00-15:00	Technology
1219	Is the sebum RNA transcriptome analysis technique capable of non-invasively diagnosing Parkinson's disease?	Sunday, September 29	13:00-15:00	Technology
1220	The study of evaluating the impact of simulating indoor environments using virtual reality on gait in Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1221	Initiation of AT-HOME PD2, a Remote Observational Study of Parkinson's Disease Clinical Trial Participants	Sunday, September 29	13:00-15:00	Technology
1222	The Feasibility and Practical utility of Virtual Visits for Patients with Parkinson's disease in Different World Regions	Sunday, September 29	13:00-15:00	Technology
1223	Wearable Device for Real-Time Prevention of Freezing-of-Gait in Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1224	Developing Composite Digital Measures for Tracking Parkinson's Disease (PD) Progression using a Comprehensive Machine Learning-based Framework	Sunday, September 29	13:00-15:00	Technology
1225	Codesigning Tech with Patients - Insights from the Quantitative and Qualitative Analysis of Three Technologies used in Patients With Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1226	Reliability of real-world walking activity and gait assessment in people with Parkinson's disease - how many hours and days are needed?	Sunday, September 29	13:00-15:00	Technology
1227	A Scoping Review of Epidural Spinal Cord Stimulation in the Treatment of Multiple Movement Disorder Symptoms	Sunday, September 29	13:00-15:00	Technology
1228	Acceptability of Digital Health Technologies in Early Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology

1229	AI-Powered Eyewear for Routine Facial Expression Analysis in Parkinson's Disease: Study design and goals	Sunday, September 29	13:00-15:00	Technology
1230	Acceptability and user experience of the electronic versions of the MDS-UPDRS and MDS-NMS scales	Sunday, September 29	13:00-15:00	Technology
1231	TeleHD: Feasibility, Validity and Value of Telemedicine in Huntington Disease	Sunday, September 29	13:00-15:00	Technology
1232	Automatic detection of Freezing of gait in Parkinson's disease with IMU: validation of a deep learning algorithm in the home.	Sunday, September 29	13:00-15:00	Technology
1233	Haptics' use in extended reality environments for Parkinson disease: A systematic review	Sunday, September 29	13:00-15:00	Technology
1234	Speech Biomarkers for Dysarthria in Parkinson's Disease — Clinical Validation Across two Languages	Sunday, September 29	13:00-15:00	Technology
1235	Gender specificity in AI-Based Screening Diagnostics of Parkinson's Disease (Brainphone Project)	Sunday, September 29	13:00-15:00	Technology
1236	Balancing Act: Smartphone Data and Machine Learning in Movement Disorder Classification	Sunday, September 29	13:00-15:00	Technology
1237	Reliability of Digital Measures in Parkinson's Disease and Their Implications for Sample Size Calculations	Sunday, September 29	13:00-15:00	Technology
1238	A non-linear index can detect early postural instability in people with Parkinson's disease: Enhancing perspectives on the utilization of cost-effective technologies.	Sunday, September 29	13:00-15:00	Technology
1239	How many days are required to reliably estimate diverse digital mobility outcomes from various gait domains with a lower back sensor in people with Parkinson's disease?	Sunday, September 29	13:00-15:00	Technology
1240	The novel Gait Cycle Detection Network (GCDN) for Video based gait Analysis based on single 2D RGB video	Sunday, September 29	13:00-15:00	Technology
1241	Continuous Monitoring of Hypomimia in Parkinson's disease using a Sensor-equipped Cap	Sunday, September 29	13:00-15:00	Technology
1242	Use of social media and health information technology among caregivers of Alzheimer's disease and other neurological conditions: Secondary analysis of the 2022 Health Information National Trend (HINTS) Survey	Sunday, September 29	13:00-15:00	Technology
1243	SMArT-PD: A Clinical Decision Support System for the Management of Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology

1244	Optimal measuring height and validation of 2D-LiDAR based analysis system for spatiotemporal gait parameters	Sunday, September 29	13:00-15:00	Technology
1246	Role of Telemedicine- Versus Outpatient-Based Initiation And Management of Atkins Diet Therapy In Postmenopausal Women With Drug-Resistant Parkinson's Disease During The COVID-19 Pandemic	Sunday, September 29	13:00-15:00	Technology
1247	Unlocking Movement Disorder Specialist Capacity and Mitigating Risk: a Platform Solution for Cost Reduction and Care Optimization in Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1249	Free-living digital mobility outcomes in Parkinson's disease patients with and without freezing of gait: what can they tell us?	Sunday, September 29	13:00-15:00	Technology
1250	Prediction of falls in PD over 5 years using kinematic data and machine learning	Sunday, September 29	13:00-15:00	Technology
1251	The Use of Biometric Feedback Devices for Stratification of Deep Brain Stimulation (DBS) Eligibility and Treatment Response in Parkinson Disease	Sunday, September 29	13:00-15:00	Technology
1252	Physical activity in patients with atypical parkinsonian syndromes - Collection of real-world data	Sunday, September 29	13:00-15:00	Technology
1253	Pressure Sensor Insole Gait Assessment for Parkinson's Disease patients: A longitudinal study.	Sunday, September 29	13:00-15:00	Technology
1254	Identification of Fall Risk in Patients with Parkinson's Disease Through Telemonitoring	Sunday, September 29	13:00-15:00	Technology
1255	Wearable sensors and AI in Parkinson's disease - How continuous symptom and treatment response monitoring can enable better clinical decision making - Interim results from an observational study	Sunday, September 29	13:00-15:00	Technology
1256	Sex differences of gait at self-determined speed in neurodegenerative parkinsonism	Sunday, September 29	13:00-15:00	Technology
1257	Examining and contextualizing free-living heart rate using multiple wearable sensors: a potential approach for assessing autonomic dysfunction in Parkinson's disease?	Sunday, September 29	13:00-15:00	Technology
1258	Determining the optimal filtering method for the removal of gait-related movement artefacts from EEG acquired from People with Parkinson's Disease	Sunday, September 29	13:00-15:00	Technology
1259	Digital health technology (DHT) derived features as sensitive measures of disease progression in early Parkinson's disease under stable dopaminergic treatment	Sunday, September 29	13:00-15:00	Technology

1260	Measuring Motor Improvement with a Wearable Device in a Parkinson Disease Patient undergoing Subcutaneous Levodopa Carbidopa Infusion	Sunday, September 29	13:00-15:00	Technology
1261	Empower-PD: "An Exploratory Investigation of Accelerometer Data on Parkinson's Patients' Motor Symptoms and the Correlation with Quality of Life."	Sunday, September 29	13:00-15:00	Technology
1262	eHealth - an Opportunity for personalized Care? - Healthcare Professionals' Technology Acceptance in the Care of Parkinson's Patients	Sunday, September 29	13:00-15:00	Technology
1263	Characterization of Muscle activity before and during Freezing of Gait Episodes	Sunday, September 29	13:00-15:00	Technology
1264	Baseline Data of the Mobilise-D Parkinson Cohort	Sunday, September 29	13:00-15:00	Technology
1265	Speech Analysis and Machine Learning can Aid in Identifying Different Neurological Disorders	Sunday, September 29	13:00-15:00	Technology
1266	Creating myPPMI: an Online Portal to Deliver Study Participant Content	Sunday, September 29	13:00-15:00	Technology
1267	Comparative Analysis of GAITRite and Moticon Digital Insoles for Gait Assessment in Parkinson's Disease Patients Before and After Levodopa Administration	Sunday, September 29	13:00-15:00	Technology
1268	Speech Processing System for Parkinson's Disease Using Mixed Reality	Sunday, September 29	13:00-15:00	Technology
1269	A Device Agnostic Pipeline for Gait Detection and Assessment in Free-living and Clinical Environments	Sunday, September 29	13:00-15:00	Technology
1270	Get Ready a mobile phone app a solution for patient engagement/remote management	Sunday, September 29	13:00-15:00	Technology
1271	Artificial Intelligence Opportunities for Diagnostics of Dementia via Speech (Brainphone Project)	Sunday, September 29	13:00-15:00	Technology
1272	Gait and turning during daily life across the spectrum of normal, prodromal, early and moderate Parkinson's disease	Sunday, September 29	13:00-15:00	Technology
1273	Medication Effects on Bradykinesia and Tremor in Parkinson's Disease, Measured by Wearable Sensors	Sunday, September 29	13:00-15:00	Technology
1274	Distinguishing Parkinson's disease from atypical Parkinsonian syndrome using multistage deep learning based on dopamine transporter imaging	Sunday, September 29	13:00-15:00	Technology
1275	Determining the Direction of segmented DBS Micro Electrodes through the EEG	Sunday, September 29	13:00-15:00	Technology

1276	Motor Onset of Parkinson's disease: the proximal limbs are first	Sunday, September 29	13:00-15:00	Technology
1277	Spinocerebellar ataxia type 2 specific microRNAs may have an effect on neurodegeneration.	Monday, September 30	13:00-15:00	Ataxia
1278	How does the PPP2R2B mutation alter neuronal cytoskeletal structure in SCA12	Monday, September 30	13:00-15:00	Ataxia
1279	iPSC-Based Modeling of SCA12 for Targeted Therapeutic Screening	Monday, September 30	13:00-15:00	Ataxia
1280	Spectrum of polysomnographic abnormalities in a cohort of sporadic late onset ataxia patients	Monday, September 30	13:00-15:00	Ataxia
1281	Spinocerebellar Ataxia 34: ELOVL4 Recurrent Mutation in a Different Family	Monday, September 30	13:00-15:00	Ataxia
1282	White Matter Tractography in Spinocerebellar Ataxia type 1 and 2 in comparison with Healthy Controls	Monday, September 30	13:00-15:00	Ataxia
1283	Variant Ataxia Telangiectasia: A Novel ATM Gene Mutation With Disabling Tremor and Response to Deep Brain Stimulation	Monday, September 30	13:00-15:00	Ataxia
1284	Novel Partial Gene Deletion in CaCNA1A Presenting with Gait Ataxia, Vertigo, and Abnormal Eye Movements	Monday, September 30	13:00-15:00	Ataxia
1285	Case Report of Spinocerebellar Ataxia 13 Presenting with Pure Cerebellar Ataxia	Monday, September 30	13:00-15:00	Ataxia
1286	Increased Risk of Suicidal Ideation in Patients with Spinocerebellar Ataxias	Monday, September 30	13:00-15:00	Ataxia
1287	The first Indian patient with Hereditary Spastic Paraparesis type 42 due to a de novo SLC33A1 variant	Monday, September 30	13:00-15:00	Ataxia
1288	Fixel Analysis of Diffusion Imaging in Cerebellar Tracts as a Quantitative Marker of Disease Progression in Spinocerebellar Ataxia	Monday, September 30	13:00-15:00	Ataxia
1289	Spinocerebellar ataxia type 2 (SCA2) and Seizures: Is There a Correlation?	Monday, September 30	13:00-15:00	Ataxia
1290	4-Aminopyridine improves downbeat nystagmus in SCA27b: A case report	Monday, September 30	13:00-15:00	Ataxia
1291	Progressive Myoclonic Ataxia: Neuroinflammation and Autoantibodies Against Inhibitory Synapses and Herpes Viruses	Monday, September 30	13:00-15:00	Ataxia

1292	Mixed Cerebellar Ataxia in a Patient with a Novel FAT2 Gene Variant Associated with SCA45	Monday, September 30	13:00-15:00	Ataxia
1293	CANVAS and Sleep Disorder: a Prospective Cross-Sectional Study	Monday, September 30	13:00-15:00	Ataxia
1294	Pulmonary Dysfunction in Friedreich's Ataxia (FRDA)	Monday, September 30	13:00-15:00	Ataxia
1295	A Head-Turning Case of SCA10 with Dystonia	Monday, September 30	13:00-15:00	Ataxia
1296	Phenotypic spectrum and natural history of POLR3A-associated spastic ataxia	Monday, September 30	13:00-15:00	Ataxia
1297	Two-year longitudinal evaluation of ataxia and brain structural changes in RFC1-related disorder	Monday, September 30	13:00-15:00	Ataxia
1298	Association of expanded CAG repeat with autonomic function in Spinocerebellar Ataxia Type-2 (SCA-2)	Monday, September 30	13:00-15:00	Ataxia
1300	Clinical and Genetic Profile of Spinocerebellar Ataxias in a Tunisian Cohort	Monday, September 30	13:00-15:00	Ataxia
1301	When the Nephrologist calls... Ataxia, Seizures, and Hypokalemia – EAST syndrome and KCJN10 gene mutation	Monday, September 30	13:00-15:00	Ataxia
1302	Prevalence of Heterozygous ATP7B Mutation in Patients with Movement Symptoms	Monday, September 30	13:00-15:00	Ataxia
1303	Autosomal recessive spastic ataxia of Charlevoix–Saguenay: Case report with 3 family members affected.	Monday, September 30	13:00-15:00	Ataxia
1304	Autosomal recessive cerebellar ataxias: a Tunisian cohort of 168 patients	Monday, September 30	13:00-15:00	Ataxia
1305	Electrophysiological study of 122 Tunisian patients with autosomal recessive cerebellar ataxia	Monday, September 30	13:00-15:00	Ataxia
1306	Ataxia Telangiectasia Diagnosis in Lower-Middle-Income Countries: A Case Report	Monday, September 30	13:00-15:00	Ataxia
1307	NGS diagnosis rate in a combined cerebellar ataxia and spastic paraplegia series from southern Spain	Monday, September 30	13:00-15:00	Ataxia
1308	Opsoclonus after Covid-19 infection	Monday, September 30	13:00-15:00	Ataxia

1309	Spinocerebellar Ataxia Type 4: a Novel Polyglycine Disease caused by GGC Repeat Expansion in ZFH3.	Monday, September 30	13:00-15:00	Ataxia
1310	Dentate Deep Brain Stimulation for Cerebellar Ataxia: Long Term Outcomes	Monday, September 30	13:00-15:00	Ataxia
1311	Substantia Nigra Degeneration In Spinocerebellar Ataxia 2 And 7 Using Neuromelanin-Sensitive Imaging	Monday, September 30	13:00-15:00	Ataxia
1312	Ataxia, tremor, fasciculations and hemiparesis in a GBA1 heterozygous female carrier	Monday, September 30	13:00-15:00	Ataxia
1313	Ataxia and Gait Improvement in Relapsing-Remitting Multiple Sclerosis After Transcranial Magnetic Stimulation (TMS): A Case Study	Monday, September 30	13:00-15:00	Ataxia
1314	Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit	Monday, September 30	13:00-15:00	Ataxia
1315	Progressive Cerebellar Ataxia as the Predominant Symptomatology of SGP-7 Compound Heterozygote Pathogenic Variants related HSP-7	Monday, September 30	13:00-15:00	Ataxia
1316	Alterations in the Daily Living Gait and Mobility during the Day and Night among Individuals with Cerebellar Ataxia, SCA3: An Exploratory Study	Monday, September 30	13:00-15:00	Ataxia
1317	Spinocerebellar Ataxia Type 49 presenting with Early onset Dystonia-Ataxia in an Indian Female	Monday, September 30	13:00-15:00	Ataxia
1318	An Unusual and Treatable Cause of Cerebellar Ataxia and Dystonia: Homozygous COQ4 Gene Mutation	Monday, September 30	13:00-15:00	Ataxia
1319	Assessment of Cerebellar Ataxia Severity in Patients with Posterior Cranial Fossa Tumors Using CASAS Scale	Monday, September 30	13:00-15:00	Ataxia
1320	Nonmotor symptoms in Spinocerebellar ataxia type 12 (SCA 12)	Monday, September 30	13:00-15:00	Ataxia
1321	FGF14 repeat expansions: prevalence and case series of patients with SCA27B from Slovakia	Monday, September 30	13:00-15:00	Ataxia
1322	Evaluating Pharmacological Interventions for Friedreich Ataxia: A Network Meta-Analysis of Randomised Trials	Monday, September 30	13:00-15:00	Ataxia
1323	Expanding the Phenotype of a Novel Mutation in ELOVL4 and the Differential Diagnosis of the Hot Cross Bun Sign	Monday, September 30	13:00-15:00	Ataxia
1324	Predicting Disease Severity in Friedreich's Ataxia through Wearable Monitoring and Machine Learning.	Monday, September 30	13:00-15:00	Ataxia

1325	CAPRIN1 defect: a new severe neurodegenerative disorder with childhood dementia, myoclonus-ataxia, and sensorimotor neuropathy	Monday, September 30	13:00-15:00	Ataxia
1326	Atypical spinocerebellar ataxia (SCA) type 16 as initial presenting migraine and mild ataxia with cerebellar atrophy	Monday, September 30	13:00-15:00	Ataxia
1327	Clinico-radiological and genetic profile of patients with Ataxia with Oculomotor apraxia type-2 (AOA2)- A case series from India	Monday, September 30	13:00-15:00	Ataxia
1328	paraneoplastic cerebellar ataxia: a rare cause of late-onset ataxia	Monday, September 30	13:00-15:00	Ataxia
1329	A Rare Case Of Young Onset Ataxia: Spinocerebellar Ataxia Type 40	Monday, September 30	13:00-15:00	Ataxia
1330	Effects of Transspinal Magnetic Stimulation (TsMS) in Patients Diagnosed with Spinocerebellar Ataxia 3 (SCA 3)	Monday, September 30	13:00-15:00	Ataxia
1331	Seminoma resulting in rapidly progressive cerebellar syndrome with associated dual positive kelch-like protein 11 (KLHL11) IgG and leucine zipper 4 (LUZP4)–immunoglobulin G (IgG) antibodies.	Monday, September 30	13:00-15:00	Ataxia
1332	Superficial siderosis; a case review	Monday, September 30	13:00-15:00	Ataxia
1333	Diagnostic challenges with novel SCA variants: A case of STUB1 mutation	Monday, September 30	13:00-15:00	Ataxia
1334	Spastic Ataxia Associated with Congenital Myasthenia Related to the VAMP1 Gene: Report of an Affected Family in Brazil.	Monday, September 30	13:00-15:00	Ataxia
1335	Transcranial Direct Current Stimulation and Neurofunctional Physical Therapy Improves Motor and Cognitive Symptoms in a Patient with Type 1 Spinocerebellar Ataxia – A Case Report	Monday, September 30	13:00-15:00	Ataxia
1336	Movement disorders secondary to neurocysticercosis: a case report from Bolivia	Monday, September 30	13:00-15:00	Ataxia
1337	Non Classified Spinocerebellar Ataxia-like Syndrome due to GYG-1 gene mutation with TPM3, GEMIN5 and DES mutations in a Peruvian family	Monday, September 30	13:00-15:00	Ataxia
1338	Volatile solvent abuse and Cerebellar ataxia: A case series	Monday, September 30	13:00-15:00	Ataxia
1339	Progressive Apraxia of Speech as a Presenting Symptom of Spinocerebellar Ataxia Type 2	Monday, September 30	13:00-15:00	Ataxia

1340	Friedreich's ataxia: A descriptive study of a Tunisian cohort	Monday, September 30	13:00-15:00	Ataxia
1341	Progressive cerebellar ataxia in primary Sjögren's syndrome: a case report	Monday, September 30	13:00-15:00	Ataxia
1342	Tremulous Machado-Joseph Disease	Monday, September 30	13:00-15:00	Ataxia
1343	A study on the phenomenological analysis of Spinocerebellar Ataxia type 12 revealing a dystonic imprint	Monday, September 30	13:00-15:00	Ataxia
1344	Syndrome of Progressive Ataxia with Palatal Tremors (PAPT) with Hypertrophied Bilateral Inferior Oligives in a young Indian Female	Monday, September 30	13:00-15:00	Ataxia
1345	The Profile of Cerebellar Ataxia in Neurology Patients at National Tertiary Referral Hospital in Indonesia	Monday, September 30	13:00-15:00	Ataxia
1346	Neuropsychiatric Manifestations in Patients with Degenerative Cerebellar Ataxias from Serbia	Monday, September 30	13:00-15:00	Ataxia
1350	Ektacytometry in Neuroacanthocytosis	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1351	A Novel Mutation of NKX2-1 Gene: A Rare Presentation of Chorea	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1352	Choreoballism due to Bisphosphonate-Induced Antiphospholipid Syndrome: A Case Report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1353	Phenotypic Aspects of Huntington's Disease-Like 2 in Brazil and the World: Literature Review	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1354	Choreiform Movements Secondary to Sarcoidosis Without Central Nervous System Granulomatosis	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1355	The clinical features, neuroimaging and outcomes of diabetic striatopathy: a retrospective study at tertiary hospital in Vietnam	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1356	Cryptococcal meningitis as a rare cause of acute generalized chorea: a report of an interesting case	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1357	Challenges of Huntington's disease and chorea in Guinea: the benefits of genetic testing in tropical environments	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1358	Spectrum of Non-HD Hereditary Chorea- Case Series from An Indian Movement Disorder Centre	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)

1359	Chorea after MRgFUS for the treatment of essential tremor: A case report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1360	A Rare Case of Hemicorea Secondary to Giant Perivascular Space: A Case Report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1361	Clonazepam as First-Line Therapy for Post-Hypoxic Chorea: A Case Report and Discussion	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1363	Chorea Acanthocytosis Misdiagnosed as Functional Movement Disorder	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1364	Bilateral Fronto-Temporal Lobar Atrophy: An Atypical Magnetic Resonance Imaging Finding in Neuroacanthocytosis	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1365	Hyperkinetic Movements Related to COVID-19 Vaccine	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1366	Fahr's Disease Presenting as Chorea: A Rare Case Report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1367	Reversible Hemichorea-Hemiballismus-Hemifacial Spasm in Diabetic Striatopathy	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1368	Choreoacanthocytosis: The First Genetically Confirmed Cases From Algeria	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1369	Cortical Pencil Lining in Brain MRI of a Patient with Chorea and Hepatic Cirrhosis	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1370	Acute Chorea in The Emergency Department Related to Systemic Lupus and Antiphospholipid Syndrome: A Case Report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1371	Diabetic striatopathy with stroke - like symptoms: A case report	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1372	Severe chorea, ballistic and dystonic movement disorder due to intracerebral hemorrhage in subthalamic nucleus	Monday, September 30	13:00-15:00	Choreas (Non-Huntington's Disease)
1374	Myoclonus and Encephalitis as an Adverse Event of mRNA COVID-19 Vaccine	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1375	Rapid Onset Kinematic Effects of Thalamic/Subthalamic DBS in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1376	A Phase IIb Double-Blind Placebo-Controlled Randomized Cross-Over Clinical Trial of Sodium Oxybate in Isolated Focal Laryngeal Dystonia	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy

1378	DystoniaDBSNet: A novel deep learning biomarker of predictive treatment outcomes in dystonia	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1379	The Impact of Standardized Recommendations on the Management of Initial and Refractory Pediatric Status Dystonicus	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1380	Intraventricular baclofen and bilateral pallidotomy in a pediatric patient with acquired generalized dystonia and refractory status dystonicus	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1381	Motor and Quality of Life Outcomes of Deep Brain Stimulation for Pediatric Dystonia – CHILD-DBS Registry	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1382	Deep Brain Stimulation in Dystonia: Investigating Differential Response by Dystonia Distribution	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1383	Effective Management of Generalized Dystonia with Unilateral Deep Brain Stimulation - Killing Two Birds with One Stone?	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1384	Cervical Dystonia Objectively Measured with Wearable Sensor System	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1385	Bilateral Deep Brain Stimulation in Subthalamic Nucleus versus Globus Pallidus Internus for refractory dystonia	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1387	Effect of bilateral internal segment of the globus pallidus deep brain stimulation on acquired multifocal dystonia due to natural gas intoxication.	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1388	Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1389	Subacute Combined Degeneration in Wilson Disease: Treatment Dilemma	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1390	Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical Dystonia: Potential for a New Treatment Paradigm with DaxibotulinumtoxinA	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1391	Lifestyle Medicine for Cervical Dystonia: a New View on Treatment	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1392	Efficacy and Safety of DaxibotulinumtoxinA-lanm for Injection in Adults with Cervical Dystonia: Pooled Global Analysis of ASPEN-1 and ASPEN-1-CN	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy
1393	Treatment of Craniofacial Dystonias with Methylphenidate: A Case Series.	Monday, September 30	13:00-15:00	Dystonia: Clinical Trials and Therapy

1395	Paroxysmal non-kinesigenic dyskinesia: atypical neurological presentation of Lyme neuroborreliosis	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1396	A Comprehensive Evaluation of the Non-Motor Symptoms, Quality of Life and Caregiver Burden in Patients with Idiopathic Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1397	Dystonia and Impact on Employment in a Spanish Cohort	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1398	Kinematic Features of Voluntary and Involuntary Head Movements in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1399	Intrafamilial phenotypic variability of DYT-ANO3: Analyzing 14 affected members with a novel variant	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1400	Rare Missense Variants in KCNJ10 Are Associated with Paroxysmal Kinesigenic Dyskinesia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1401	Relationship Between Non-Motor Symptoms, Kinematic Features, and Quality of Life in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1402	Impact of Surrounding Audio-Visual Complexity on Symptomatology of Laryngeal Dystonia: A Virtual Reality Study	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1403	Effect Of Botulinum Toxin On Non-Motor Symptoms In Adult-Onset Idiopathic Focal Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1404	Real-World Diagnosis of Chronic Migraine in Patients With Cervical Dystonia Analyzed by Botulinum Neurotoxin Treatment Exposure: an Epidemiologic Perspective	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1405	Rapidly Progressive Pallidopyramidal Syndrome related to Parkin gene mutation	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1406	KMT2B-Related Dystonia And DBS: Tertiary Center Experience	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1407	Clinical Outcomes and Local Field Potential Characteristics in Bilateral GPi DBS in 2 cases of X-Linked Dystonia Parkinsonism	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1408	DYT-KMT2B generalized dystonia managed with GPi-DBS	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1409	Clinical Characteristics and Management Practices of Pediatric Status Dystonicus	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1410	Genetic Variant in the VPS16 Gene in a 44-year-old Patient with Generalized Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology

1411	Ataxic-spastic gait: a form of presentation of DYT5/DYT-GCH1	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1413	Common Genotypes Of Dystonia and Response To DBS; Tertiary Center Experience	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1414	Phenotypic Variability in Combined Parkinsonism-Dystonia and Isolated Idiopathic Dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1415	Longitudinal Assessment of Dystonic Symptoms in Rapid-Onset Dystonia-Parkinsonism: genetic dystonia symptoms vary over time	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1416	The Yips in Golf: Is it a Task-Specific Dystonia ?	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1417	Cervical dystonia after cerebellar stroke and medullary hemorrhage	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1418	Challenges in Wilson disease management in a resource-limited country: a case report from a tertiary center	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1420	Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1421	A 24-year-old female with 18p deletion syndrome presenting with rapidly worsening dystonia	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1422	Expanding the concept of “occupational dystonia”: data from the Italian Dystonia Registry	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1423	Recrudescence of a Compensated Hemidystonia-hemiatrophy Syndrome After COVID-19 Infection	Monday, September 30	13:00-15:00	Dystonia: Epidemiology, Genetics, Phenomenology
1424	Chronic striatal cholinergic agonist infusion as a model of dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1425	Structural and Functional Brain Alterations in Laryngeal Dystonia: A Coordinate-Based Activation Likelihood Estimation Meta-Analysis	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1426	Task-Based Functional Imaging in Task-Specific Focal Dystonia during Dystonia-Related and -Unrelated Tasks	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1427	Precision Functional Mapping of Therapeutic Response in Task-specific Focal Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1428	Exploring the non-invasive epigenetic screening test for hereditary dystonia DYT-KMT2B	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging

1429	GABA in the Basal Ganglia Tracks Motor Severity and Response to BoNT Treatment in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1430	Abnormal brain iron metabolism influences neural function in isolated laryngeal dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1431	Increased cerebellar grey matter in writer's cramp patients: a morphometric signature of symptom compensation	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1432	Severe Acute Spinal Cord Injury Due to Isolated Generalized Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1433	Neural Signatures of Laryngeal Dystonia during Asymptomatic Tasks of Sequential and Learned Finger-Tapping	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1435	Writing dysfluency associates with basal ganglia network dysfunction in writer's cramp dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1436	Two Cases of Moyamoya Syndrome-Associated Chorea and Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1437	Temporal prediction in cervical dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1438	Visual Temporal Discrimination Threshold using a Virtual Reality Paradigm in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1439	Investigating Impaired Perceptual Decision Making in Cervical Dystonia: A novel paradigm integrating Behavioural and Neural measures	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1440	Altered [18F]VAT Uptake Supports Cholinergic Dysfunction in Isolated Adult-Onset Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1441	Beyond the Surface: Electromyography in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1442	A Survey of Immunological Mechanisms in Cervical Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1443	Dysfluent Writing Behavior Associates with Reduced Striatal-cerebellar Connectivity in Writer's Cramp Dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1444	Transcranial magnetic stimulation target comparison identifies motor network reorganization associated with behavioral improvement in writer's cramp dystonia	Monday, September 30	13:00-15:00	Dystonia: Pathophysiology, Imaging
1445	Somnolence-Related Events Over Time with Valbenazine Treatment for Chorea Associated with Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease

1446	Validation of the Korean Version of the Huntington's Disease Quality of Life Battery for Carers	Monday, September 30	13:00-15:00	Huntington's Disease
1447	Epidemiology of Huntington's Disease in Latin America: A Systematic Review and Meta-analysis.	Monday, September 30	13:00-15:00	Huntington's Disease
1449	Study of Relationship Between Homocysteine, Folic Acid And Vitamin B12 Levels In Serum of Juvenile HD Children.	Monday, September 30	13:00-15:00	Huntington's Disease
1450	Association between Morbidity and Social Vulnerability in Patients with Huntington Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1451	The use of modelling in Huntington's disease	Monday, September 30	13:00-15:00	Huntington's Disease
1452	Amyloid Pathology and its association with Cognitive Status in Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1453	Skin Tau Quantification as a Novel Biomarker in Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1454	Nocturnal Blood Pressure, Non-Dipping, Psychosis And Non-Motor Symptoms In Early Stages Of Huntington's Disease Patients	Monday, September 30	13:00-15:00	Huntington's Disease
1455	Exploring Correlations between Mutant Huntingtin, NfL, and MRI in Huntington's Disease: A Multimodal Analysis	Monday, September 30	13:00-15:00	Huntington's Disease
1456	Time-Restricted Eating in Huntington's Disease: Review of the Literature and a Proposed Clinical Trial	Monday, September 30	13:00-15:00	Huntington's Disease
1457	Physical Activity Levels and Demographic Characteristics in Individuals with Huntington's Disease: Insights from the ENROLL-HD Database in an Argentinian Movement Disorder Center	Monday, September 30	13:00-15:00	Huntington's Disease
1458	Machine Learning-Driven Exploration of Epigenetic Patterns in Huntington's Disease: Understanding Histone Modification Dynamics	Monday, September 30	13:00-15:00	Huntington's Disease
1459	Non-motor symptoms in people with Huntington's disease: use and validation of the MDS Non-Motor Scale (MDS-NMS)	Monday, September 30	13:00-15:00	Huntington's Disease
1460	Modifiable factors associated with Huntington's disease progression in presymptomatic participants: explained longitudinal machine learning modelling	Monday, September 30	13:00-15:00	Huntington's Disease
1461	Serum urea and clinical outcomes in Huntington's disease	Monday, September 30	13:00-15:00	Huntington's Disease

1462	Longitudinal Relationship Between Brain Metabolism and Clinical Changes in Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1463	Muscle mass, body fat mass, and nutrition in patients with Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1464	Identifying Key Features for Predicting Clinical Status in Huntington's Disease Patients Using Raw Speech Samples: a Lightweight Machine Learning Approach	Monday, September 30	13:00-15:00	Huntington's Disease
1465	Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1466	Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington's Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data	Monday, September 30	13:00-15:00	Huntington's Disease
1467	Asymmetric Symptomatic Huntington's Disease in a Patient with Intermediate Range Trinucleotide Repeats	Monday, September 30	13:00-15:00	Huntington's Disease
1468	Correlation Between Low Hemoglobin Levels and Gait Dysfunction in Huntington's Disease: An Exploratory Study	Monday, September 30	13:00-15:00	Huntington's Disease
1469	Predicting Clinical Status of Patients with Huntington's Disease from Raw Speech Samples, a Lightweight Machine Learning Approach	Monday, September 30	13:00-15:00	Huntington's Disease
1470	Clinical and Epidemiological Aspects of Neuropsychiatric Features in Patients with Huntington Disease in Chile	Monday, September 30	13:00-15:00	Huntington's Disease
1471	One-year longitudinal decline in spatial location memory in Huntington's disease	Monday, September 30	13:00-15:00	Huntington's Disease
1472	The characteristic and prognostic role of blood inflammatory markers in patients with Huntington's disease from China	Monday, September 30	13:00-15:00	Huntington's Disease
1473	Baseline lipid traits and the clinical characteristics and disease progression in Huntington's disease	Monday, September 30	13:00-15:00	Huntington's Disease
1474	Measuring Cortisol Levels in Persons with Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1475	Ataxia and Parkinsonism Related with CAG Expansion Size in a Cohort of Huntington's Disease in the Brazilian Amazon Region.	Monday, September 30	13:00-15:00	Huntington's Disease
1476	Remote monitoring of upper limb function in Huntington's disease using a wearable sensor	Monday, September 30	13:00-15:00	Huntington's Disease

1477	Genetic Migration Dynamics: Unraveling the Influence of Internal Migration on Huntington's Disease Prevalence in the Amazonas State.	Monday, September 30	13:00-15:00	Huntington's Disease
1479	Assessing Executive Function in HD: Comparing the One Touch Stockings of Cambridge and Zindamatrix's Tower-Z as Components of the HD-CAB	Monday, September 30	13:00-15:00	Huntington's Disease
1480	Deciphering the Huntington's Disease Research Landscape: A Comprehensive Bibliometric and Trend Analysis	Monday, September 30	13:00-15:00	Huntington's Disease
1481	Mapping the Efficacy Landscape: A Network Meta-Analysis of Pharmacological Interventions in Huntington's Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1482	Huntington's Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies	Monday, September 30	13:00-15:00	Huntington's Disease
1483	Shifting Paradigms In Huntington's Disease Research: A Five-Year Scopus-Based Bibliometric Exploration	Monday, September 30	13:00-15:00	Huntington's Disease
1484	The Spectrum of Presenting Phenotypes in Childhood Onset Huntingtons Disease	Monday, September 30	13:00-15:00	Huntington's Disease
1485	Deep Brain Stimulation for Post-Hypoxic Myoclonus: A Case Correlating Local Field Potentials to Clinical Outcome	Monday, September 30	13:00-15:00	Myoclonus
1486	Closed-Loop Spinal Cord Stimulation: A Case Report on a Novel Therapeutic Approach for Post-Hypoxic Myoclonus	Monday, September 30	13:00-15:00	Myoclonus
1487	Treatment of Post-hypoxic Myoclonus using Bilateral Subthalamic Nuclei Deep Brain Stimulation	Monday, September 30	13:00-15:00	Myoclonus
1488	Lance – Adams Syndrome: a Case Series from Vietnam	Monday, September 30	13:00-15:00	Myoclonus
1490	Cortical myoclonus in DHDDS: the multifaced presentation of a single movement disorder	Monday, September 30	13:00-15:00	Myoclonus
1491	When Jerks and Stumbles Become More Than Just Clumsiness	Monday, September 30	13:00-15:00	Myoclonus
1492	Mechanism Study of Familial Cortical Myoclonic Tremor with Epilepsy Type 1 Caused by Pentanucleotide Repeat Expansion in the SAMD12 Gene	Monday, September 30	13:00-15:00	Myoclonus
1493	Childhood onset progressive myoclonus and ataxia in a patient with novel TBC1D2B gene mutation	Monday, September 30	13:00-15:00	Myoclonus
1494	A Poor Prognosis for Acute Post Hypoxic Myoclonus with Status Epilepticus: A Case Report	Monday, September 30	13:00-15:00	Myoclonus

1495	Unusual Causes of Reversible Myoclonus: A Video Based Case Series	Monday, September 30	13:00-15:00	Myoclonus
1496	A 12-year Longitudinal Study of Sleep in Huntington's disease: Insomnia is associated with greater Cognitive Impairment and Disease Activity	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1497	Medication Refractory Restless Legs Syndrome: Real-World Experience	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1498	Disrupted Sleep Circadian Rhythms and Brain Disorders: A Large Prospective Cohort Study	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1499	Pitolisant as adjunct therapy for refractory restless legs syndrome	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1500	Serum Alpha-Synuclein Levels Are Decreased in Patients with Restless Legs Syndrome and Restored by Intravenous Iron Therapy in Correlation with Ferritin	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1501	Racial Disparities in Hospitalization Characteristics among Native Hawaiians, Pacific Islanders and Asian American Subgroups with Restless Legs Syndrome	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1502	Benzodiazepines in the Management of Restless Legs Syndrome: A Systematic Review and Meta-Analysis	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1503	A case of Restless Abdominal Syndrome An Uncommon Variant of Restless Leg Syndrome	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1504	Handwriting Features in Patients with Isolated REM Sleep Behaviour Disorder	Monday, September 30	13:00-15:00	Restless Legs Syndrome and Other Sleep Disorders
1506	Comparison in Therapeutic Outcome of Ultrasound-Guided Botulinum Injections for Limb Spasticity Versus Dystonia	Monday, September 30	13:00-15:00	Spasticity
1508	The Clinical and Genetic Characteristics of HSP Patients by WES Sequencing Combined with MLPA	Monday, September 30	13:00-15:00	Spasticity
1509	Clinical and Genetic Characteristics in a Chinese Cohort of Complex Spastic Paraplegia Type 4	Monday, September 30	13:00-15:00	Spasticity
1510	Krabbe disease: A systematic review and evidence-based guideline for diagnosis	Monday, September 30	13:00-15:00	Spasticity
1511	Identifying and Managing Spasticity in Neurological Shoulder Dysfunction	Monday, September 30	13:00-15:00	Spasticity
1512	Effectiveness of abobotulinumtoxinA in adults with lower limb spasticity: Results from the AboLiSh real world observational study	Monday, September 30	13:00-15:00	Spasticity

1513	Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real world practice	Monday, September 30	13:00-15:00	Spasticity
1514	Feasibility and Comprehensibility of the SMD Decision Tree for Early Recognition of Spasticity	Monday, September 30	13:00-15:00	Spasticity
1516	Pathways for diagnosis and multimodal management, including botulinum neurotoxin therapy, in shoulder conditions following central lesions	Monday, September 30	13:00-15:00	Spasticity
1517	Social Media Listening Study to Understand the Journey and Unmet Needs of Patients Living With PSS	Monday, September 30	13:00-15:00	Spasticity
1518	A Review of the Genetic Spectrum of Hereditary Spastic Paraplegias in the Middle East and North Africa Region	Monday, September 30	13:00-15:00	Spasticity
1519	Impact of Patient Input on the Study Execution of a Prospective, Epidemiological Study	Monday, September 30	13:00-15:00	Spasticity
1520	Goal Attainment and Ambulation With Increasing Doses of IncobotulinumtoxinA: A Post Hoc Analysis of the TOWER Study	Monday, September 30	13:00-15:00	Spasticity
1521	Moderate-to-severe upper limb spasticity patterns in the elderly are improved following treatment with incobotulinumtoxinA: a pooled analysis	Monday, September 30	13:00-15:00	Spasticity
1522	Ultrasound Assessment of Collagen Content in Contracted and Non-contracted Muscle Areas: A Comparative Study	Monday, September 30	13:00-15:00	Spasticity
1523	Spastic paraparesis and paroxysmal dystonia associated with a novel mutation in ATP1A3 in a spanish family	Monday, September 30	13:00-15:00	Spasticity
1524	Improvement in upper limb spasticity patterns in the elderly following treatment with incobotulinumtoxinA: a pooled analysis	Monday, September 30	13:00-15:00	Spasticity
1525	Deep Brain Stimulation in Tourette Syndrome: Characteristics of Three Patients Pre and Post Implantation	Monday, September 30	13:00-15:00	Tics/Stereotypies
1526	Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from a Phase IIb Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome	Monday, September 30	13:00-15:00	Tics/Stereotypies
1527	Randomized Controlled Trial of Supplementary Motor Area Transcranial Direct Current Stimulation in Tourette Syndrome	Monday, September 30	13:00-15:00	Tics/Stereotypies
1528	Gaps in Diagnosing and Treating Tic Disorders in Latin America: A Survey of Healthcare Workers	Monday, September 30	13:00-15:00	Tics/Stereotypies

1529	Mapping the Landscape of Tourette Syndrome Research: A Bibliometric Analysis	Monday, September 30	13:00-15:00	Tics/Stereotypies
1530	Leg Stereotypy Syndrome: Phenomenological and Quantitative Analysis	Monday, September 30	13:00-15:00	Tics/Stereotypies
1531	Exploring youth with Tourette syndrome whose tics first manifested after age 12	Monday, September 30	13:00-15:00	Tics/Stereotypies
1532	Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect	Monday, September 30	13:00-15:00	Tremor
1533	Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1535	How Common is Essential Tremor in Germany? A Real-World Claims Data Analysis	Monday, September 30	13:00-15:00	Tremor
1536	A prospective study on post-stroke Holmes tremor with analysis of semiology, lesion topography and treatment outcomes	Monday, September 30	13:00-15:00	Tremor
1537	Validation of a New Patient-reported Outcome Scale for the Assessment of Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1538	Disease Burden and Treatment in Patients With Essential Tremor in the United States: Real-World Evidence From a Cross-Sectional Survey of Physicians and Patients	Monday, September 30	13:00-15:00	Tremor
1539	Effectiveness of VIM DBS for Head Tremor in Essential Tremor Patients: A Single-center Experience	Monday, September 30	13:00-15:00	Tremor
1540	Social phobia, anxiety and depression in patients with essential tremor	Monday, September 30	13:00-15:00	Tremor
1541	Utilizing a tablet-based digital drawing to discriminate Parkinson's disease from essential tremor	Monday, September 30	13:00-15:00	Tremor
1542	The Fazekas scale score and the occurrence of adverse events after MRgFUS thalamotomy, is there a relationship?	Monday, September 30	13:00-15:00	Tremor
1543	Reliability of neurophysiological and cerebral tremor features in Parkinson's disease	Monday, September 30	13:00-15:00	Tremor
1544	REM sleep behavior disorder and Prodromal Parkinson's Disease in patients with Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1545	Tractography-guided versus Clinical Determination of the Most Effective Contact for Tremor Control in Patients with Deep Brain Stimulation - A Clinical Trial	Monday, September 30	13:00-15:00	Tremor

1546	Dentato-Rubro-Thalamic Tract Deep Brain Stimulation for Essential Tremor: Stimulation Parameters and Clinical Outcomes	Monday, September 30	13:00-15:00	Tremor
1547	Magnetic resonance-guided focused ultrasounds (MRgFUS) thalamotomy for disabling tremor secondary to multiple sclerosis.	Monday, September 30	13:00-15:00	Tremor
1548	Dual Pathways of Holmes Tremor Suggested from the Experience of Deep Brain Stimulation	Monday, September 30	13:00-15:00	Tremor
1549	Cortical response to proprioceptive stimulation in orthostatic tremor - a magnetoencephalography study	Monday, September 30	13:00-15:00	Tremor
1550	Effects of Loading, Tapping Performance, and Ballistic Movements on Postural Tremor Features in Patients with Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1551	A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor: ELATE Trial	Monday, September 30	13:00-15:00	Tremor
1552	Axial Tremor does not correlate with Poor Balance in Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1553	Treatment Patterns in Essential Tremor: Real-World Evidence from Germany	Monday, September 30	13:00-15:00	Tremor
1554	Clinical differentiation between dystonic tremor and Parkinson's disease based on tremor characteristics	Monday, September 30	13:00-15:00	Tremor
1555	Classification of Tremor and Myoclonus: An Explainable Machine Learning Approach	Monday, September 30	13:00-15:00	Tremor
1556	Age of Onset and Choice of First-line Therapy in Essential Tremor Patients	Monday, September 30	13:00-15:00	Tremor
1557	Functional neurological disorders might be a frequent cause of slow orthostatic tremor: insights from a case series.	Monday, September 30	13:00-15:00	Tremor
1558	Characteristics and Treatment Patterns of Patients Newly Diagnosed With Essential Tremor: A Retrospective Claims Database Analysis in the US	Monday, September 30	13:00-15:00	Tremor
1559	Prevalence of Phosphorylated Alpha-Synuclein in Skin Biopsies of Essential Tremor Patients	Monday, September 30	13:00-15:00	Tremor
1560	Low intensity focused pulsed ultrasound as a treatment of essential tremor: a case series	Monday, September 30	13:00-15:00	Tremor
1561	Artificial Intelligence Approaches for Tremor Detection and Classification from Hand-drawn Spirals	Monday, September 30	13:00-15:00	Tremor

1562	Association of cognition and other clinical characteristics of individuals with Essential Tremors	Monday, September 30	13:00-15:00	Tremor
1563	Assessing the Economic Impact of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Real-World Evidence Study Protocol	Monday, September 30	13:00-15:00	Tremor
1564	Sleep profiles in patients with Essential Tremor and Essential Tremor Plus: Polysomnography Insights	Monday, September 30	13:00-15:00	Tremor
1565	Secondary orthostatic tremor associated with hyperthyroidism: A case report	Monday, September 30	13:00-15:00	Tremor
1566	Combining EMG and Simulation-Based Biomarkers to Enhance Parkinson's Resting Tremor Diagnosis	Monday, September 30	13:00-15:00	Tremor
1567	Genetic Analysis of UK Kindreds with Familial Tremor in The Global Parkinson's Genetics Program (GP2)	Monday, September 30	13:00-15:00	Tremor
1568	Comparative assessment of cognitive functions of patients with ET and ET plus.	Monday, September 30	13:00-15:00	Tremor
1569	Clinical Assessment Of Dysautonomia And REM Sleep Behavior Disorders in Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1570	Changes In Glucose Metabolism In Essential Tremor: Within And Beyond The Cerebello-Thalamo-Cortical Circuit	Monday, September 30	13:00-15:00	Tremor
1571	Daily-life Sensor Based Measurement of Tremor Presence and Amplitude	Monday, September 30	13:00-15:00	Tremor
1572	MRgFUS thalamotomy for essential tremor: Lesion location and clinical outcomes	Monday, September 30	13:00-15:00	Tremor
1573	Evaluating the Effect of Myofascial Release on Parkinson's Related Tremor	Monday, September 30	13:00-15:00	Tremor
1574	Tremor and dizziness in a psychiatric patient	Monday, September 30	13:00-15:00	Tremor
1575	The Intention Component of Postural Tremor in Essential Tremor	Monday, September 30	13:00-15:00	Tremor
1576	Is essential tremor-plus phenotype a prodromal phase of Parkinson's disease ?	Monday, September 30	13:00-15:00	Tremor
1577	Jaw Clonus Masquerading as Jaw Tremor in a case of Amyotrophic Lateral Sclerosis (ALS)	Monday, September 30	13:00-15:00	Tremor

1578	Feasibility of Reliable, Remote Assessment of a 13-year-old Boy Who Stopped Talking	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1579	A better understanding of Paediatric Paroxysmal Movement Disorders	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1580	Application of Neurophysiology in the Clinical Evaluation of Pediatric and Adolescent Patients with Tremor	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1581	Movement Disorders Associated with Infectious Encephalitis in Pediatric Patients	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1582	ATP8A2 Mutation in a Tunisian Family : Expanding The Clinical Spectrum	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1583	Movement Disorders In Children With Monoamine Neurotransmitter Disorders	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1584	Delineating the Molecular and Clinical Spectrum of Epilepsy-Dyskinesia Syndromes in Children (The Epilepsy-Dyskinesia Spectrum Study)	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1585	Acute Ataxia in children : a North-African Single Center Experience	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1586	Writing dystonia in children improves after chronic stimulation of globus pallidus internus	Monday, September 30	13:00-15:00	Pediatric Movement Disorders
1587	Identification and Screening of Candidate Genes for Paroxysmal Movement Disorders by Next Generation Sequencing Approach for Developing Molecular Diagnostics.	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1588	Expanding the Neurogenetic Spectrum: A Case of DEPDC5 Mutation Presenting with Unilateral Tremor and Cognitive Decline	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1589	Improving Work Up amongst Patients with Rare Movement Disorders according to Diagnostic Yield Findings– Update from Single Center Neurogenetic Clinic	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1590	Genetic Heterogeneity in Chorea-Acanthocytosis Revealed by Varying VPS13A Mutations Within a Consanguineous Family	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1591	A novel G413S mutation in the CSF1R gene causes Hereditary Diffuse Leucoencephalopathy with axonal Spheroids; clinically overlapping features of Parkinsonism	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1592	Bi-allelic BORCS5 Variants Result In A Wide Spectrum of Progressive Neurodevelopmental Disorders via Lysosomal Dysfunction	Monday, September 30	13:00-15:00	Genetics (Non-PD)

1593	Global presence and penetrance of CSF1R-Related disorder	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1594	Utility of Whole Exome Sequencing in movement disorders potentially related to Mitochondrial cytopathies	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1595	Three-Year Progression of the Postural Control Alterations in Hereditary Spastic Paraplegias	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1596	Complex Movement Disorders in Late Onset TPP1 Gene Mutation (Atypical Neuronal Ceroid Lipofuscinosis Type 2)	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1597	Expanding the phenotypic spectrum of movement disorders in 22q11.2 deletion syndrome	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1598	A Novel SLC9A1 Mutation Associated with Cerebellar Ataxia and Sensorineural Hearing Loss	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1599	Parkinsonism in combined Fragile X and XYY Syndromes: A Case Report	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1600	Clinico- radiological profile of four patients with CSF1R- related leukoencephalopathy: A case series from India	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1601	Identification of Compound Heterozygous and Novel Deep-Intronic TH Mutations in a Chinese Patient with Dopa-Responsive Dystonia	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1602	A Homozygous Variant in NAA60 is Associated with Primary Familial Brain Calcification	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1603	New Pathological Findings in an International Cohort of Hereditary Spastic Paraplegia 4 Patients	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1604	Intermediate Expansion of MARCHF6 causes FAME3 without Epilepsy	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1605	Phenotypic Variability of PRNP and Related Movement Disorders	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1606	Validation of Inertial Measurement Units and an application compared with the reference system to assess the gait in hereditary spastic paraplegia	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1607	OPTN gene associated with corticobasal syndrome: a novel multi-exon deletion and literature review	Monday, September 30	13:00-15:00	Genetics (Non-PD)
1608	ATP1A3-related disorder overlapping syndrome: a case report	Monday, September 30	13:00-15:00	Genetics (Non-PD)

1610	LRRK2 in Parkinson's Disease: A per-domain rare-variant burden study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1611	Investigating the genetic relationship between vitamin B12 deficiency and Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1612	Transcriptome analysis of proteasome and inflammation in the substantia nigra of Parkinson's disease patients: the GEO database.	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1613	GBA1 deficiency differentially affects endolysosomal trafficking in neurons and astrocytes	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1614	The functional consequences of the 'African GBA1 allele' of rs3115534 in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1615	Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1616	A Benign Course of Parkinson's Disease Associated with Different Mutations in the Glucocerebrosidase (GBA) Gene – a Case Series.	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1617	Prevalence of Parkinson's Disease and Possible Parkinsonian Syndrome in Gaucher Disease: Data From the ICGG Gaucher Registry	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1618	Slc2a13, a risk gene for Parkinson's disease associated with Snca and Lrrk2	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1619	Association of Gaucher-related and Parkinson's-private GBA1 variants with progression of PD: A longitudinal mixed model analysis.	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1620	Implications of BSCL2 Mutation in the Pathogenesis of Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1621	Genome-Wide Association Study revealing novel risk loci associated with Age at Onset of Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1622	Rare Variant Burden is Increased in Sporadic Late-onset Chinese Parkinson's Disease Patients	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1623	MDSGene Update and Expansion: Clinical and Genetic Spectrum of LRRK2 Variants in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1624	Association of polygenic risk score of the LRRK2 gene for Parkinson's disease with lysosomal hydrolase activities in the Russian Population based on genetic profile and established risk factors	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics

1625	Lysosomal network defects in parkinsonian patients carrying rare variants in lysosomal hydrolytic enzyme genes	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1626	Parkinson's disease associated SORL1 variants impair mitochondrial and endo-lysosomal function	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1627	The First of Its Kind Genetics Cohort: the Black and African American Connections to Parkinson's Disease (BLAAC PD) Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1628	The Genetic Landscape of Parkinson's Disease in an Italian Cohort and the Need for a Standardized Approach	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1629	Disease Progression in Patients with PLA2G6-related Parkinsonism: A Longitudinal Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1630	RAB32 c.213C>G (p.Ser71Arg) explains Parkinson's disease in two UK families: description of the clinical and biochemical features	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1631	LRRK2 and GBA Founder Mutations and their Interactions in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1632	Remote DNA Collection for Parkinson's Research: Insights from AccessPD	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1633	PD GENERation: a genetic analysis beyond the classical 7 Parkinson's disease genes	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1634	Long-read sequencing to identify unrevealed second hit in autosomal recessive Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1635	Association between Genetic Polymorphisms and Disease Progression in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1636	Differences in Oculometric Measures between Patients with LRRK2-associated and Idiopathic Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1637	Young-onset Parkinson's disease in a female with pathogenic deletion of the PRRT2 gene	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1638	Exploring MAPT Haplotypes in Parkinson's Disease in a Diverse Cohort: Insights from the Global Parkinson's Genetics Program	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1639	Distinct patterns of Gene Expression in Skin-biopsy Derived Fibroblasts of Patients with Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1640	Genetic Study of polymorphism of cytokines in Parkinson's disease.	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics

1641	Increased alpha-internexin levels are associated with a higher risk of Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1642	Utility of using long-read whole genome sequencing to solve exome negative early-onset and familial Parkinson's disease: a series of 106 individuals	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1643	Genome-wide Assessment of Homozygosity in Parkinson's Disease Across Diverse Ancestral Population	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1644	Understanding the earliest phases of Parkinson's disease (PD) - an expanding opportunity to study 'at-risk'/early/prodromal PD in the Global Parkinson's Genetics Program (GP2)	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1645	Genetic Modifiers of Age at Onset for Parkinson's Disease in Chinese Population	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1646	Utilizing a global network to study environmental factors relating to Parkinson's disease in the Global Parkinson's Genetics Program (GP2)	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1647	Parkinson's Families Project: A UK-Wide Study of Early Onset and Familial Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1648	Unraveling the Role of Short Tandem Repeats in Parkinson's disease, Essential tremor, and Amyotrophic lateral sclerosis: A Large Chinese Cohort Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1649	Expanding the Spectrum of Autosomal Recessive Genes Responsible for Parkinson's Disease in the Chinese Population	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1650	Assessing Genome-wide Genetic Risk for Parkinson's Disease in European Sub-Populations Across the Global Parkinson's Genetics Program and National Biobanks	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1651	Strategic Training Framework for Advancing Research Capacity through GP2	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1652	Causal effects of sarcopenia-related traits on risk and progression of Parkinson's disease: a Mendelian randomization study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1653	the role of the "unfolded protein response" and the perk pathway in parkinson's disease: study of genetic polymorphisms	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1654	Engagement of the Black and African American Community in Parkinson's Genetic Research	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1655	Studying monogenic Parkinson's disease by building a global cohort of mutation carriers	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics

1656	Comorbidities in genetic Parkinson's Disease: comparison between LRRK2, GBA1, and non-mutated PD	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1657	Contribution of Genetics to Onset of PD with Leg Tremor	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1658	Clinical And Genetic Analysis Of Patients With Parkinson's Disease -LRRK2 Variants From A Referral Centre In India	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1659	Latent Genetic Architecture of Parkinson's Disease Risk factors and Comorbidities	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1660	Sleep Characteristics in Idiopathic and Genetic Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1661	Common Genetic Variation Associated with Parkinson's Disease Biological Measures	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1662	Parkinson's Disease Risk Genotypes at the GPNMB Locus Associate with Extent of Post-mortem Lewy Pathology	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1663	Artificial intelligence: a potential predictor of GBA1-mutated genotype in Parkinson's Disease patients?	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1664	Bidirectional Relationship Between Olfaction and Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1665	Investigating Copy Number Variations in SNCA and PRKN in a Cohort of Kazakhstani Patients with Parkinson's Disease and Healthy Controls	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1666	Leveraging Large-Scale Proteomics to Identify Protein Quantitative Trait Loci and Causal Effects on Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1667	Diagnosing Young-Onset and Familial Parkinson's Disease Using an Extensive Targeted Panel	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1668	Genetic Analysis of Mendelian mutations in A Large Chinese Early-onset and Familial Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1669	Frequency of LRRK2 p.L1795F variant in Parkinson's Disease patients from Central Europe within the CEGEMOD consortium	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1670	Clinical and genetic characteristics of PLA2G6-parkinsonism in southwest of China and a review of heterogeneity of phenotype and genotype between Asian and Caucasian patients	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1671	RAB32 variant p.Ser71Arg in the ROstock PArkinson's Disease Study (ROPAD)	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics

1672	Expanding the PD GENERation Study to increase clinical genetic testing and counseling using whole genome sequencing among diverse Parkinson's disease (PD) populations	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1673	Genetic determinants of the progression of Lewy body pathology	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1674	Readiness for genetic testing among Indian movement disorder patients:A tertiary centre experience	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1675	Clinico-genetic profile of five patients with PARK-PINK1: A case series from India	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1676	Expanding Diversity of Parkinson's Disease and Related Disorders Genetic Data: from the Global Parkinson's Genetics Program	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1677	Determining and Leveraging Local Ancestry to Assess Individual-Level Risk: from the Global Parkinson's Genetics Program	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1678	5HTTLPR (44bp Ins/Del) polymorphism: Serotonergic subtype of Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1679	the role of metabotropic glutamate receptors type 3 and 5 in parkinson's disease: analysis of grm3 and grm5 genbe variants.	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1680	A UK-wide Effort for Identification of Loci for Autosomal Dominant Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1681	The Black and African American Connections to Parkinson's Disease Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1682	Young onset Dystonia-Parkinsonism, Intellectual Disability & Mineral deposits in Basal ganglia - Think "RAB39B" mutation	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1683	Understanding Parkinson's disease in Spain: genetic and clinical insights	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1684	Association of Impulse Control Disorder with GRIN2B Gene Polymorphisms in Parkinson Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1685	Frequency of Variants of Uncertain Significance in a Cohort of Early-onset Parkinson's Disease Patients	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1686	Clinical Features of dj1 Gene Mutation Causing Parkinson's Disease from Single Institution	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1688	Screening for newly PD-associated RAB32 p.S71R variant in Latin America	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics

1689	Genome-wide Survival Analysis Identified Association Between HS1BP3 and APOE loci and Dementia in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1690	Rare Variant Association Analysis in Kazakhstani Parkinson's Disease Population: Preliminary Results from GP2 CAT-PD Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1691	GBA Mutation Profile in Parkinson's Disease: Insights from a Movement Disorders Center in Brazil	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1692	The association of Severity and Monogenetic Subgroups in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1693	7year followup of Asia's first case of sporadic ATP6AP2 Mutation: α -synucleinopathy or tauopathy?	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1694	Expanding Phenotype of LRRK2 G2019S Mutation: Case Description of Two Sisters Showing Peculiar Phenomenological Traits	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1695	A Case of Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1696	Adding Parkinsonism to the Phenotypic Spectrum of FIG4-related diseases	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1697	A new phenotype-genotype correlation for FIG4 gene and Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1698	A Rare Case of Parkinson's Disease Associated With Heterozygous ATP13A2 Gene Mutation: What If There Are No Atypical Features with a Later Onset?	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1699	LRRK2 Gene Mutation in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Genetics
1700	Novel ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1701	Can Heterozygous Autosomal Recessive Mutations Cause Neurological Disease?	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1702	Laboratory changes of the liver function in the patients with Wilson's disease	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1703	Wilson's Disease : A Senegalese Series of Seven Patients Followed at Pikine National Hospital Centre (Dakar-Senegal)	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1704	DPPX Autoimmune Encephalitis Associated with Severe Multifocal Dystonia.	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases

1705	A Patient with Overlapping SPG7 mutation and MERRF	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1706	Juvenile DBP Deficiency – Case series	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1707	The NINDS Approach to Therapeutic Development for Ultra-Rare Neurological Disorders, Bridging Translational and Clinical Frontiers in Gene-based Therapy	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1709	Hemochromatosis and Movement Disorders	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1710	The Landscape of Neurodegeneration with Brain Iron Accumulation in Indian patients: Lessons from a Multicentric Cross-sectional Study	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1711	Real-life experience of switching from D-penicillamine to trientine tetrahydrochloride - a nationwide registry study	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1712	Association between Hyperglycemic Crisis Severity and Movement Disorders in Hispanic Patients with De Novo Hyperglycemia: A Cross-Sectional Study	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1713	Autosomal Recessive Spastic Ataxia Secondary a Novel SPG7 Gene Pathogenic Variant: a Case Report	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1715	Transition from Zinc Salts to Trientine Tetrahydrochloride in Wilson Disease: Clinical and Biochemical Effects over Two Years – the ZICUP study	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1716	Cardiovascular Risk Profile in Patients with Primary Familial Brain Calcification	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1717	Spectrum of Movement Disorders in Vitamin B12 Deficiency: A Case Series from India	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1718	Neurodegeneration with brain iron accumulation in pediatric population: Clinico-radiologic and genetic features	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1719	Clinical, Radiological and Genetic profile of Eight Patients with Genetically Proven Ceroid Lipofuscinosis Neuronal and Movement Disorders	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1720	Movement Disorder Presentations in Leukoencephalopathy with Calcifications and Cysts	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1721	Prevalence of immune-mediated diseases in long-term chelator therapy in Wilson’s Disease	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1722	Therapeutic challenges of long-standing chelator therapy in Wilson’s Disease	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases

1723	Autosomal Recessive GTPCH Deficiency: Redefining the Phenotypic Spectrum and Outcome	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1725	Mutation of the ATP5F1A gene associated with dystonia, spasticity, myoclonus, cognitive impairment and epilepsy – a rare case report of a patient	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1726	SLC39A8-CDG with manganese deficiency in an adult individual: a case report	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1727	Movement Disorders in Cerebrotendinous Xanthomatosis	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1728	Unraveling the Complexity of Neurodegenerative Disorders: A Case Report of PKAN Suspected in a 24-Year-Old Patient with Severe Dystonia	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1729	Movement Disorders in De Novo Hyperglycemic Crisis: Insights from a Clinical Case Series	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1730	A Unique case of Ataxia, Neuropathy, and chronic cough: CANVAS	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1731	Startle Reflex in CTNNB1 Mutations: A diagnostic Clue	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1732	Dopa-responsive ataxia with compound heterozygous variants in MRE11	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1733	Phenotypic variability of mitochondrial tRNA Ser(UCN) gene [MTTS1] mutation: First report from India	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1734	PMM2 mutation	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1735	Spastic Ataxia and Motorneuron disease as possible manifestations of ATP13A2 (PARK 9) variants	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1736	Phenomenology of Coenzyme Q10-deficiency Spinocerebellar Ataxia: Case Description Of Two Siblings And New Therapeutic Perspectives	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1737	Tetradystonics patients may be misdiagnosed?	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1738	Adult-onset Niemann-Pick C in India: phenotype and genotype	Monday, September 30	13:00-15:00	Rare Genetic and Metabolic Diseases
1739	Movement-Related Potentials Recorded Using Cerebellar Deep Brain Stimulation Leads	Monday, September 30	13:00-15:00	Neurophysiology (Non-PD)

1740	Ionic Plasticity of Midbrain GABAergic Synapses in PD Models	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1741	Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1742	Understanding diffusion in extracellular space in synucleinopathy	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1743	Complexity of fractal patterns in motor cortical oscillatory activity in rodent models of Parkinson disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1744	The Protective Effect of <i>Sutherlandia frutescens</i> in a Rotenone-Induced Rat Model of Parkinson's Disease.	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1745	Investigation of the Beta Oscillations of Local Field Potential in the Subthalamic Nucleus of the Parkinsonian Minipig Model	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1746	Real-Time Removal of Stimulus Artifact for Closed-Loop Deep Brain Stimulation by Synchronized Sample-And-Hold Artifact Blanking (SSAB): Verification in Animal Model	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1747	Optogenetic Deep Brain Stimulation Rescues Motor Behavior in a Rat Model of Mild Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1748	Can gait instability indicate the cognitive function of people with Parkinson's disease?	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1749	Association of Liver Fibrosis with Motor Deficits in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1750	Deep brain stimulation-evoked potentials as an avenue to optimize stimulation outcomes in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1751	Fatigue in PD is related to decreased efficiency of the frontal network	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1752	Oscillatory signatures of genetic Parkinson's disease patients in subthalamic macroelectrode recordings	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1753	Basal ganglia theta oscillation as a predictor of levodopa-induced dyskinesias	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1754	Clinical, Neurophysiological, and Biological Insights into Levodopa-Induced Dyskinesias	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1755	Altered levels of interleukin-6 in Parkinson's disease patients with and without Covid-19	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology

1756	Oscillatory network mapping of deep brain stimulation outcomes in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1757	Neural oscillatory dynamics in Parkinson disease and dystonia: Insights from EEG analysis	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1758	Abnormal Subthalamic Oscillations as Potential Biomarkers for Identifying the Dyskinesia-Inducing Region within the Subthalamic Nucleus in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1759	Personalized Optimization of Deep Brain Stimulation Parameters for Gait Enhancement in Parkinson's Disease: A Data-Driven Approach	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1760	Altered EEG Theta Activity Characterizes Parkinson's disease with Levodopa-induced Dyskinesia	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1761	Exploring the neural correlates of impulsivity and impulsive compulsive behaviors in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1762	Characteristics of tremor frequency oscillatory neurons in the basal ganglia and thalamus in Parkinson's tremor	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1763	Transcranial Direct Current Stimulation for Freezing of Gait in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1764	Correlation of Neural Sensing with the Volume of Neural Activation within the Desired Patient-Specific Anatomical Target in Deep Brain Stimulation for Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1765	Levels of change in interleukin-6 levels according to clinical forms of Parkinson's disease in patients with and without Covid-19	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1766	Levels of change in interleukin-6 levels according to clinical stages of Parkinson's disease in patients with and without Covid-19	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1767	Non-invasive transcranial Electrical Stimulation (tRNS and tACS) targeting the Pallidum in normal Controls and PD Patients by rotating electrical Fields	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1768	Cervical Vestibular-Evoked Myogenic Potentials in Patients with Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1769	Linear Mixed-Effect Modelling of Antisaccades in Parkinson's Disease and Progressive Supranuclear Palsy	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1770	Quantification of an Upper Limb Rigidity Network in Parkinson Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology

1771	Case Studies of Real-World Brain Sensing Showing Patient-Specific Trends to Inform Therapy Management in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1772	Temporal coordination of head and trunk during 360-degree turning in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1773	Monopolar sensing improves the efficiency of DBS programming in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1774	Maintaining Isometric Contraction in Parkinson's Disease: Effect of PD-Medication on EMG Amplitude	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1775	Quantitative Analysis of the Biomechanical Contributors during the miniBEST Clinical Scale for Assessing Risk of Falling in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1776	Clinical applications of cortical finely tuned gamma oscillations induced via subthalamic deep brain stimulation in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1777	Longitudinal Studies of LFP Activities During Acute and Chronic DBS Stimulation in PD Patients	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1778	Comparison of Monopolar and Bipolar Sensing of Beta Frequency in Parkinson's Disease of the Subthalamic Nucleus for Deep Brain Stimulation	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1779	Vestibulo-ocular reflex and cognitive dysfunction in denovo Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1780	Evaluation of theta burst transcranial ultrasound stimulation on motor cortex in Parkinson's denovo patients.	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1781	Parkinson's Disease tremor can show entrainment and distractibility with electrophysiological assessment using tapping test.	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1782	Analysing the bradykinesia features combination in people with Parkinson's disease and elderly healthy individuals	Monday, September 30	13:00-15:00	Parkinson's Disease: Neurophysiology
1783	Phenotypic characterization of an ATP13A2 knockout rat model of Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1784	Harnessing chaperone-mediated autophagy through viral-based LAMP2A overexpression in non-human primates as a Treatment of Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1785	The Inhibition of Mitochondrial NLRP3 Inflammasome Decreases Dopaminergic Cell Death in a 6-OHDA Mouse Model of Parkinson's Disease.	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1786	V-ATPase subunit V1G1 overexpression conferred the mice neuroprotection during MPTP exposure	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology

1787	Exploring the Therapeutic Potential of Microglial Modulation in Parkinson's Disease: A Study on Structural Synaptic Plasticity	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1788	Impact of sub-acute MPTP exposure on the cerebellum in adult male Balb/c mice	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1789	Alpha-synuclein aggregate pathology in the cranial sensorimotor system in a mouse model of Parkinson's disease.	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1790	Age-associated Changes in Microglial Morphology and its Role in Deciphering Susceptibility to Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1791	Altered gut microbiota composition and metabolism in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1792	IPSC-derived Cortical Neurons from Parkinson's Patients with VPS35 Mutation show Defects in Synapto- and Neurogenesis	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1793	Tissue-Engineered Nigrostriatal Pathways: An Anatomically-Inspired Model of Synucleinopathy in Human Neurons	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1794	Climate Change Indices and The Vulnerability of Parkinson's Patients in The MENA Region And North Africa: A Narrative Review	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1795	Effectiveness of Lead-Point in Parkinson's Model of STN-MER with DBS: A Study of Predicting Motor progression	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1796	Lower Incidence of Parkinson's Disease in Patients with Metabolic Syndrome or any of its Components: A Longitudinal Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1797	Predictive Accuracy of Baseline DaT-SPECT for Freezing of Gait at 5, 7, and 10-year Follow up in The PPMI Cohort	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1798	Assessing the Predictive Accuracy of Baseline Neuropsychiatric and Axial Motor Features for Freezing of Gait in Parkinson's Disease at 5-year Follow up: The PPMI Cohort	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1799	Association Between Glycated Hemoglobin (HbA1c) Levels And Motor Symptoms In Indian Subjects With Parkinson's Disease: A Cross Sectional Observational Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1800	Prokineticin-2 is highly expressed in colonic mucosa of early Parkinson's disease patients	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1801	Do Proton Pump Inhibitors Increase the Risk of Parkinson's Disease? A systematic review and meta-analysis	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology

1802	Determining Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical Data	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1803	Eye Blink Rate and Putamen DaTScan Covariation in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1804	Putaminal dopamine modulates movement motivation in Parkinson's disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1805	The potential role of monocytes a-synuclein and lipids as predictors of PD.	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1806	The role of pathology validation on the association between smoking and Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1807	Muscle Augmentation Paradox: Contrasting Therapeutic Approaches in Myasthenia Gravis and Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1808	Sexual Dimorphism in Clinical Subtypes, Biomarkers and Disease Progression of Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1809	Deep Brain Stimulators in Parkinson's subthalamic nucleus: A Study of Decade Follow-Up	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1810	A pathology-validated study to investigate the role of Uric Acid in Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1811	Neuropeptide Alterations in Parkinson's Disease: A Meta-Analysis	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1812	Reduced plasma levels of various cell signaling molecules in patients with Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1813	Environmental Risk Factors for Parkinson's Disease in the Nigeria Parkinson's Disease Research Network	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1814	Neuroprotective Action of Exogenous Melatonin in Parkinson Disease Patients and its Impact on Daily Routine: a Systematic Review	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1815	Effects of Sample Collection Methods on Skin Sebum Volatilome Composition in Parkinson's Disease Patients - a Methodological Pilot Study	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1816	Women with Parkinson's disease: exploring the occurrence of hormone-related symptom fluctuations and associated care	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1817	Study of Cytokine profile in a Tunisian Parkinson's Disease cohort	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology

1818	Plasma biomarkers for rapid eye movement sleep behavior disorder in Parkinson's disease: a prospective cohort study	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1819	Genetic Variants and Levodopa Response in Parkinson's Disease: Insights from MAO-B and DAT1 Polymorphisms	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1820	www.PregSpark.com, introducing the International Pregnancies and Parkinson's Registry	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1821	Pregnancy and delivery in women with Parkinson's disease: A case series	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1822	Levels of ferritinemia in Parkinson's disease patients who underwent Covid-19	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1823	Differentiating the Local Field Potential Oscillations in Low and Beta Range in Parkinson's and Dystonic Movement Disorder	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1824	A Risk of Thromboembolic Complications In Patients With Parkinson's Disease	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1825	Alterations in Monoamine Metabolites in Parkinson's Disease: A Meta-Analysis	Monday, September 30	13:00-15:00	Parkinson's Disease: Pathophysiology
1830	Comprehensive Strategy for Increasing Clinical Research Participation of Black and Hispanic Patients with Parkinsonism	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1831	Burden of Movements Disorders at Initiative Plus Center Hospital	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1833	Can Square Wave Jerks Differentiate Progressive Supranuclear Palsy from Parkinson's Disease? A Scoping Review	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1834	Dynamic video-assessment of axial postural abnormalities in parkinsonism: feasibility and pilot analysis	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1835	Effect of Diabetes Mellitus on the Phenotype of Parkinson's Disease	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1836	Movement disorders in patients with central nervous system tuberculosis: A systematic review	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders

1837	The “Cat Killer’s Disease”: Lived Experience of Parkinson’s disease Patients in Ethiopia	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1838	Muscle co-contraction in people with Parkinson’s disease suffering from freezing of gait	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1839	Longitudinal Gait Speed Analysis at Prodromal and Early Stage of Parkinson’s Disease	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1840	Decline in functionality according to WHODAS 2.0 associated with disease progression in people with Parkinson's disease	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1841	Developing composite measures that track physical activity change in people with early-stage Parkinson’s disease using machine learning and wearable sensors	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1842	Association between Walking Pace, Brain Structure, and Risk of Parkinson's Disease and Atypical Parkinsonism in the UK Biobank	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1843	Effects of Osteopathic Manipulative Treatment (OMT) on Lower Extremity Muscle Characteristics in Parkinson’s Disease (PD) Patients	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1844	Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1845	Evaluation of unsteadiness in patients with dystonia	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1846	A Curious Case of Bilateral Hemifacial Spasm after Treatment of Acne Vulgaris	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1847	Clinical spectrum of repetitive behaviours and neuroimaging findings in adult patients with neurological Disorders: a cross-sectional Observational study	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1848	Misdiagnosing Movement Disorders on a Terciary Academic Center in the Caribbean: A Series of Cases	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders

1849	Apraxia of eyelid opening in patients with movement disorders	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1850	Lingual-Masticatory Myorhythmia and Palatal Tremor as a Presentation of Anti-IgLON5 Disease	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1851	Proposed framework to evaluate the ability of digital measures to track early stage Parkinson's disease progression	Monday, September 30	13:00-15:00	Phenomenology and Clinical Assessment of Movement Disorders
1852	Identifying Barriers and Facilitators to Accessing Care for Members of the Black Diaspora and Hispanic People Affected by Parkinson Disease: A Qualitative Study	Monday, September 30	13:00-15:00	Education in Movement Disorders
1853	Movement Disorders Knowledge Among Medical Professionals in Central Asia	Monday, September 30	13:00-15:00	Education in Movement Disorders
1854	Opportunities for Medical Knowledge Self-Assessment in Movement Disorder Fellowship	Monday, September 30	13:00-15:00	Education in Movement Disorders
1855	Educational Programs for Patients with Parkinson disease and Deep Brain Stimulation: Scoping Review	Monday, September 30	13:00-15:00	Education in Movement Disorders
1856	Lessons from the COVID-19 Lockdown: A Novel Mentorship Program for Young Neurosurgeons, Neurologists and Medical Students	Monday, September 30	13:00-15:00	Education in Movement Disorders
1857	Education Levels on Diagnostic Delay Phase and Initial Symptom Perception Among Hispanic Patients with Parkinson's Disease: A Cross-Sectional Study	Monday, September 30	13:00-15:00	Education in Movement Disorders
1858	What you should know about your patient.	Monday, September 30	13:00-15:00	Education in Movement Disorders
1859	Investigating Interrater Reliability of the Unified Huntington's Disease Rating Scale Motor Component Between Learner and Experienced Rater	Monday, September 30	13:00-15:00	Education in Movement Disorders
1860	Improving awareness of motor fluctuations in Parkinson's Disease: an educational patient support program using a waist-worn device.	Monday, September 30	13:00-15:00	Education in Movement Disorders
1861	Benefits of Parkinson's Team Training Are Maintained Long-Term	Monday, September 30	13:00-15:00	Education in Movement Disorders
1862	Engage, Educate and Empower: Parkinson's Research Advocates from the Black and African American Community	Monday, September 30	13:00-15:00	Education in Movement Disorders
1863	Matrix in the Classroom: Augmented Reality's Role in the Transformation of Neuroanatomy Education	Monday, September 30	13:00-15:00	Education in Movement Disorders

1864	EMPOWER-PD: Testing and evaluation of an 8-week co-created Self-management program tailored People with Parkinson`s disease and their caregivers in an interventional follow-up study	Monday, September 30	13:00-15:00	Education in Movement Disorders
1865	Boosting Parkinson's Disease Diagnosis: How Training Ethiopian Healthcare Workers and Enhancing Community Level Awareness Led to a Surge in Case Identification	Monday, September 30	13:00-15:00	Education in Movement Disorders
1866	Initiating a Hybrid-Modality International Movement Disorders Fellowship: A Collaborative Effort Among Latin American Countries	Monday, September 30	13:00-15:00	Education in Movement Disorders
1867	Territorial inventory of training needs in nursing home for the support of patients with Parkinson's syndrome	Monday, September 30	13:00-15:00	Education in Movement Disorders
1868	Vegetables and fruits to relieve constipation: Do Parkinson's disease patients know them?	Monday, September 30	13:00-15:00	Education in Movement Disorders
1869	Beyond Memory:A Brain Health Awareness Kit for Spanish-speaking Communities	Monday, September 30	13:00-15:00	Education in Movement Disorders
1873	How Botulinum Toxin Transformed the American Food Industry	Monday, September 30	13:00-15:00	History of Movement Disorders
1874	A Post-mortem Study on Striatal Glia and Blood Brain Barrier Integrity in Aging and PD Asian-Indians.	Monday, September 30	13:00-15:00	Other
1875	Evaluation of Neurotransmitter and Co-transmitter Expression in the Aging Human Locus Coeruleus: Relevance to Neurodegenerative Disorders.	Monday, September 30	13:00-15:00	Other
1876	Selective subthalamic DBS improved non-motor disorders without affecting weight gain in parkinsonism	Monday, September 30	13:00-15:00	Other
1877	A Study of Age-related Changes in Galanin Expression in the Neuropil and Associated Boutons in the Human Locus Coeruleus.	Monday, September 30	13:00-15:00	Other
1878	Botulinum Toxin A Usage in Movement Disorder Division: A Retrospective Chart Review	Monday, September 30	13:00-15:00	Other
1879	Addressing Patient Needs: Enhancing Patient-Centered Care at the Movement Disorders Center	Monday, September 30	13:00-15:00	Other
1880	Behind the Prison Gates - Creating a nurse led Parkinson`s healthcare pathway at HMP Dartmoor Prison, UK.	Monday, September 30	13:00-15:00	Other
1881	Parkinson`s disease and Myasthenia Gravis: a case report and literature review	Monday, September 30	13:00-15:00	Other

1882	Clinical and Radiologic Predictors for a Longer Benefit of Cerebrospinal Fluid Decompression in Normal Pressure Hydrocephalus	Monday, September 30	13:00-15:00	Other
1883	Scoping Review of Caregiver Burden in Parkinson's Disease	Monday, September 30	13:00-15:00	Other
1884	Understanding Patient and Care Partner Educational Preferences in Atypical Parkinsonism	Monday, September 30	13:00-15:00	Other
1885	Utility of Serum α -synuclein Seed Amplification Assay as a Parkinson's Disease Biomarker	Monday, September 30	13:00-15:00	Other
1886	Clinico-radiological Spectrum and Predictors of Disease Severity in Neurological Wilson Disease: A Single Center Observational Study.	Monday, September 30	13:00-15:00	Other
1887	Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods	Monday, September 30	13:00-15:00	Other
1888	Patient-reported changes from normal in individuals with prodromal and early-motor Parkinson's disease: a scoping review	Monday, September 30	13:00-15:00	Other
1889	Antibody-mediated movement disorders: a single-centre retrospective study	Monday, September 30	13:00-15:00	Other
1890	Late-onset neurologic Wilson's disease: case series	Monday, September 30	13:00-15:00	Other
1891	The Pro-LBD Study Investigating Early Detection, Prognosis, and Biomarkers of Prodromal Lewy Body Diseases	Monday, September 30	13:00-15:00	Other
1892	Imaging the Nigrostriatal Pathway in Patients with Idiopathic Normal Pressure Hydrocephalus and Parkinsonism	Monday, September 30	13:00-15:00	Other
1893	Increasing access to Deep Brain Stimulation for an underserved patient population: A retrospective cohort from an urban hospital in a diverse county in the USA.	Monday, September 30	13:00-15:00	Other
1894	Patient and Caregiver Experiences with Tardive Dyskinesia: Emotions, Challenges, and Unmet Needs in the Patient Journey	Monday, September 30	13:00-15:00	Other
1895	Predictors of Response to Botulinum Toxin Treatment in Patients With Hemifacial Spasm:A Prospective Study	Monday, September 30	13:00-15:00	Other
1896	Device-aided Recording of Gait Parameters and Motor Fluctuations in Patients with advanced Parkinson's disease in the Home Environment	Monday, September 30	13:00-15:00	Other

1897	Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study	Monday, September 30	13:00-15:00	Other
1898	Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study	Monday, September 30	13:00-15:00	Other
1899	Co-morbid Hypertension and Diabetes and the Relationship to Parkinson's Disease Motor Phenotype in the Nigeria Parkinson's Disease Research Network Registry	Monday, September 30	13:00-15:00	Other
1900	GAD-Positive Versus GAD-Negative Stiff Person Syndrome: A Retrospective Study	Monday, September 30	13:00-15:00	Other
1901	Movement Disorders in the Emergency: New Insights	Monday, September 30	13:00-15:00	Other
1902	Anosognosia for hardware-related complications in deep brain stimulation	Monday, September 30	13:00-15:00	Other
1903	Movement Disorders in Anti-IGLON5 Antibody Disease	Monday, September 30	13:00-15:00	Other
1904	Preventing Medication Errors for Hospitalized People with Parkinson's Disease – Results of Six Months of Proactive Intervention	Monday, September 30	13:00-15:00	Other
1905	Tremors Vs. Tremors: the first music album from Parkinson's tremors	Monday, September 30	13:00-15:00	Other
1906	Idiopathic Parkinson's disease and Normal pressure Hydrocephalus – a tale of two sisters	Monday, September 30	13:00-15:00	Other
1907	Hyposmia is Associated with Positive CSF α -Synuclein Seeding in Normal Pressure Hydrocephalus	Monday, September 30	13:00-15:00	Other
1908	Movement Disorders in Autoimmune Encephalitis: A case series of 11 cases.	Monday, September 30	13:00-15:00	Other
1909	Seeking Traditional Healers in Movement Disorders: a pilot study in two African Countries	Monday, September 30	13:00-15:00	Other
1910	Triple threat: A rare case of a patient with 3 co-existent autoimmune antibodies causing autonomic and movement disorder	Monday, September 30	13:00-15:00	Other
1911	Lower plasma piperine levels in Parkinson's disease: a PPMI metabolomics analysis	Monday, September 30	13:00-15:00	Other
1912	Enhancing iRBD diagnosis through 2D video analysis: a machine learning approach	Monday, September 30	13:00-15:00	Other

1913	Satisfaction with telemedicine of patients with movement disorders on the Pacific coast of Colombia.	Monday, September 30	13:00-15:00	Other
1914	Deep Brain Stimulation for Primary Refractory Tinnitus: A Systematic Review	Monday, September 30	13:00-15:00	Other
1915	Demographics of Botulinum toxin therapy population representative to demographics in Essex County, USA	Monday, September 30	13:00-15:00	Other
1916	Dandy-Walker syndrome. A case study.	Monday, September 30	13:00-15:00	Other
1917	Wilson's Disease About A Complex Case	Monday, September 30	13:00-15:00	Other
1918	Neurophenomenological Aspects of Monocular Visual Hallucinations in Charles Bonnet Syndrome in a patient with Parkinson's Disease	Monday, September 30	13:00-15:00	Other
1919	Instrument-supported Gait Analysis Characterizes Gait Domain Changes in Patients with Suspected Normal Pressure Hydrocephalus – a Retrospective Study	Monday, September 30	13:00-15:00	Other
1920	Can We Rid Uganda of the Societal Myth That Parkinson's Disease Is Witchcraft?	Monday, September 30	13:00-15:00	Other
1921	Autoimmune Movement Disorders: An Illustrative Case Series of 8 Patients.	Monday, September 30	13:00-15:00	Other
1922	PD Young Ambassadors: A Peer-led, Community-Based Intervention to Raise PD Awareness in the Hispanic Communities of Chicago.	Monday, September 30	13:00-15:00	Other
1923	Adult Onset Spastic Paraplegia in TUBB4A Leukodystrophy	Monday, September 30	13:00-15:00	Other
1924	Delayed movement disorders after usage of desomorphine-"crocodile". Clinical case.	Monday, September 30	13:00-15:00	Other
1925	Movement disorders in Brain Sagging Syndrome- A Systematic Review	Monday, September 30	13:00-15:00	Other